<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003285" GROUP_ID="PVD" ID="565501030922191006" MERGED_FROM="" MODIFIED="2013-07-17 10:59:57 +0100" MODIFIED_BY="Marlene Stewart" REVIEW_NO="601" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-07-17 10:59:57 +0100" MODIFIED_BY="Marlene Stewart">
<TITLE>Homocysteine lowering interventions for peripheral arterial disease and bypass grafts</TITLE>
<CONTACT MODIFIED="2013-07-17 10:59:57 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="15801" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gerard</FIRST_NAME><LAST_NAME>Stansby</LAST_NAME><POSITION>Professor of Vascular Surgery</POSITION><EMAIL_1>Gerard.Stansby@nuth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>University of Newcastle upon Tyne</ORGANISATION><ADDRESS_1>Framlington Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE24HH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2336161 ext: 26204</PHONE_1><FAX_1>+44 191 2225979</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-17 10:59:57 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="58101036010735430743110819104321" ROLE="AUTHOR"><FIRST_NAME>Alina</FIRST_NAME><LAST_NAME>Andras</LAST_NAME><POSITION>Senior Health Services Researcher</POSITION><EMAIL_1>alinaro@hotmail.com</EMAIL_1><EMAIL_2>alina.andras@nuth.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Freeman Hospital</ORGANISATION><ADDRESS_1>Newcastle upon Tyne Hospitals NHS Foundation Trust</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE7 7DN</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="15801" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gerard</FIRST_NAME><LAST_NAME>Stansby</LAST_NAME><POSITION>Professor of Vascular Surgery</POSITION><EMAIL_1>Gerard.Stansby@nuth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>University of Newcastle upon Tyne</ORGANISATION><ADDRESS_1>Framlington Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE24HH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2336161 ext: 26204</PHONE_1><FAX_1>+44 191 2225979</FAX_1></ADDRESS></PERSON><PERSON ID="15752" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Monica</FIRST_NAME><LAST_NAME>Hansrani</LAST_NAME><POSITION>Vascular Surgeon</POSITION><EMAIL_1>Monica.Hansrani@stees.nhs.uk</EMAIL_1><EMAIL_2>mhansrani@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>James Cook Hospital</ORGANISATION><CITY>Middlesborough</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-04-30 08:59:12 +0100" MODIFIED_BY="Karen Welch">
<UP_TO_DATE>
<DATE DAY="12" MONTH="1" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-08 14:51:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-07-08 14:51:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>New author has joined author team, searches rerun, two new studies included, three new studies excluded. Review now no longer an empty review. Conclusions changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-05 08:41:02 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Searches rerun, two new studies included, three new studies excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-28 14:17:02 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-28 14:17:02 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-16 11:06:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Added Plain Language Summary and acknowledgements. Made minor copy edits to reference list and text. Updated formatting of headers. Added units to values given in the text. Updated dates of any changes to review. No new references found in trial search; no changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-16 11:07:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Minor copy edits made.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-03-11 13:49:42 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-03-11 13:49:42 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-03-11 13:49:42 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The authors (AA, GS) are supported by a programme grant form the NIHR.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-01-28 14:15:33 +0000" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-01-28 14:15:24 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by a programme grant from the NIHR.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-07-15 09:44:03 +0100" MODIFIED_BY="Karen Welch">
<SUMMARY MODIFIED="2013-07-15 09:39:30 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-07-14 06:09:33 +0100" MODIFIED_BY="[Empty name]">Homocysteine lowering interventions for peripheral arterial disease (PAD) and bypass grafts</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-15 09:39:30 +0100" MODIFIED_BY="[Empty name]">
<P>Homocysteine is one of the amino acids, the building blocks for proteins. High levels of homocysteine in the blood are associated with narrowing or blocking of arteries (atherosclerosis). However, it is not clear that the homocysteine itself causes the problem. Blood levels of homocysteine can be normalised by taking folic acid, vitamins B12 and B6, or betaine.</P>
<P>People with PAD have poor blood flow in their legs caused by atherosclerosis narrowing or blocking their arteries. Symptoms include a limited ability to exercise or walk without developing cramping pains in the legs. Although such people can be treated surgically (such as by a bypass graft) or radiologically (by balloon angioplasty), there is an appreciable risk of failure of the treatment within 12 months, mainly because the arteries narrow and close up again (restenosis). High levels of homocysteine (hyperhomocysteinaemia) may contribute to this restenosis and lowering homocysteine levels may help.</P>
<P>We looked at studies where treatments to lower homocysteine were used in people with PAD and hyperhomocysteinaemia. Two trials with 161 participants with PAD were included in this review. One trial showed a significant  improvement in the ankle brachial index (ABI) in participants treated daily with 400 &#956;g folic acid or 5-methyltetrahydrofolate (5-MTHF). A second trial showed that there was no difference in ABI in participants who received a multivitamin B supplement compared with placebo. None of the other predefined primary outcomes (mortality and rate of limb loss) were assessed in these studies. More research about the effect of homocysteine lowering therapy on the clinical progression of disease in people with PAD and hyperhomocysteinaemia is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-07-15 09:44:03 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-07-14 05:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Elevated plasma levels of the amino acid homocysteine (hyperhomocysteinaemia) are associated with narrowing or blocking of the arteries (atherosclerosis). Treatment to lower homocysteine levels has been shown to be both effective and cheap in healthy volunteers. However, the impact of reducing homocysteine levels on the progression of atherosclerosis and patency of the vessels after treatment for atherosclerosis is still unknown and forms the basis for this review. This is the second update of a review first published in 2002.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-14 05:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of plasma homocysteine lowering therapy on the clinical progression of disease in people with peripheral arterial disease (PAD) and hyperhomocysteinaemia including, as a subset, those who have undergone surgical or radiological intervention.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-07-14 06:00:13 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Peripheral Vascular Disease Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched January 2013) and CENTRAL (2012, Issue 12). Trial databases were searched by the TSC (January 2013) for details of ongoing and unpublished studies. We also searched the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-07-14 06:02:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trials in which participants with PAD and hyperhomocysteinaemia were allocated to either homocysteine lowering therapy or no treatment, including participants before and after surgical or radiological interventions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-15 09:44:03 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trial quality and extracted the data. Information on adverse events was collected from the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-07-14 06:06:38 +0100" MODIFIED_BY="[Empty name]">
<P>Two randomised trials with a total of 161 participants were included in this review. The studies did not report on mortality and rate of limb loss. One randomised trial with a total of 133 participants showed that there was a significant improvement in ankle brachial index (ABI) in participants who received folic acid compared with placebo (mean difference (MD) 0.07, 95% confidence interval (CI) 0.04 to 0.11, P &lt; 0.001) and in participants who received 5-methyltetrahydrofolate (5-MTHF) versus placebo (MD 0.05, 95% CI 0.01 to 0.10, P = 0.009). A second trial with a total of 18 participants showed that there was no difference (P non-significant) in ABI in participants who received a multivitamin B supplement (mean ± SEM: 0.7 ± 01) compared with placebo (mean ± SEM: 0.8 ± 0.1). No major events were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-05-01 09:38:09 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, no recommendation can be made regarding the value of treatment of hyperhomocysteinaemia in peripheral arterial disease. Further, well constructed trials are urgently required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-07-15 09:43:08 +0100" MODIFIED_BY="Karen Welch">
<BACKGROUND MODIFIED="2013-07-15 09:40:31 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-07-14 12:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>The prevalence of peripheral arterial disease (PAD) is currently believed to be around 20% in adults over 60 years of age in the UK, and increases with increasing age (<LINK REF="REF-Coni-1992" TYPE="REFERENCE">Coni 1992</LINK>; <LINK REF="REF-Dormandy-1991" TYPE="REFERENCE">Dormandy 1991</LINK>; <LINK REF="REF-Meijer-1998" TYPE="REFERENCE">Meijer 1998</LINK>; <LINK REF="REF-NICE-2012" TYPE="REFERENCE">NICE 2012</LINK>). However, only a third to a fifth of those affected actually present to their general practitioner with symptoms (<LINK REF="REF-Criqui-1997" TYPE="REFERENCE">Criqui 1997</LINK>; <LINK REF="REF-Diehm-2004" TYPE="REFERENCE">Diehm 2004</LINK>; <LINK REF="REF-Stoffers-1996" TYPE="REFERENCE">Stoffers 1996</LINK>). Of these, 90% have angiographic evidence of concomitant coronary artery disease and 40% have carotid artery disease as determined by duplex ultrasound scanning (<LINK REF="REF-Tierney-2000" TYPE="REFERENCE">Tierney 2000</LINK>), while their mortality from any cardiovascular cause is two to eight times that of the general population (<LINK REF="REF-Bainton-1994" TYPE="REFERENCE">Bainton 1994</LINK>; <LINK REF="REF-Leng-1996" TYPE="REFERENCE">Leng 1996</LINK>; <LINK REF="REF-Voller-2002" TYPE="REFERENCE">Voller 2002</LINK>). In patients with critical limb ischaemia mortality may be as high as 50% at five years (<LINK REF="REF-Adam-2005" TYPE="REFERENCE">Adam 2005</LINK>; <LINK REF="REF-Stoyioglou-2004" TYPE="REFERENCE">Stoyioglou 2004</LINK>). There is growing evidence that even people with asymptomatic PAD have a two to three times greater cardiovascular mortality and morbidity than the general population (<LINK REF="REF-Hooi-2001" TYPE="REFERENCE">Hooi 2001</LINK>; <LINK REF="REF-Leng-1996" TYPE="REFERENCE">Leng 1996</LINK>; <LINK REF="REF-Shammas-2007" TYPE="REFERENCE">Shammas 2007</LINK>).</P>
<P>The demand for therapeutic interventions has been increasing steadily with the advent of treatments such as angioplasty (<LINK REF="REF-Pell-1994" TYPE="REFERENCE">Pell 1994</LINK>; <LINK REF="REF-White-2007" TYPE="REFERENCE">White 2007</LINK>) and an increasingly aging population. Currently 20% to 30% of angioplasties and bypasses fail within 12 months, requiring further interventions. The major cause of failure of these treatments is restenosis (re-narrowing of the artery after treatment) within the treated vessel or bypass. Any further procedure will be susceptible to the same problem and so current research centres on prevention via a myriad of pharmaceutical agents, changes in technique, endothelial cell seeding of grafts, intravascular irradiation and gene therapy. As yet none of these techniques has had a significant impact on restenosis rates and none of them addresses the high morbidity and mortality in these patients from coronary or cerebrovascular disease (<LINK REF="REF-Hermans-1992" TYPE="REFERENCE">Hermans 1992</LINK>; <LINK REF="REF-Inglis-2013" TYPE="REFERENCE">Inglis 2013</LINK>; <LINK REF="REF-Thompson-1994" TYPE="REFERENCE">Thompson 1994</LINK>; <LINK REF="REF-Verin-1995" TYPE="REFERENCE">Verin 1995</LINK>; <LINK REF="REF-Yla_x002d_Herttuala-2000" TYPE="REFERENCE">Yla-Herttuala 2000</LINK>).</P>
<P>McCully first suggested that there might be an association between homocysteine, a non-essential amino acid, and atherosclerosis (<LINK REF="REF-McCully-1969" TYPE="REFERENCE">McCully 1969</LINK>) when he observed that patients with a rare genetic enzyme deficiency, leading to elevated levels of homocysteine in the blood, developed atherosclerosis prematurely in their second and third decades.</P>
<P>Although the initial work looked at levels of homocysteine &gt; 100 µmol/L in the blood, milder forms of hyperhomocysteinaemia with levels of 15 to 100 µmol/L caused by heterozygous abnormalities in the enzyme cystathionine-B-synthase (CBS), thermolabile forms of methylene tetrahydrofolate reductase (MTHFR), abnormalities in the methionine synthase complex or dietary deficiencies of the vitamin co-factors folate, B12 and pyroxidine have been shown to be independent graded risk factors for all forms of cardiovascular disease, including deep vein thrombosis (<LINK REF="REF-Boushey-1995" TYPE="REFERENCE">Boushey 1995</LINK>; <LINK REF="REF-Cattaneo-1999" TYPE="REFERENCE">Cattaneo 1999</LINK>; <LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>; <LINK REF="REF-den-Heijer-1998" TYPE="REFERENCE">den Heijer 1998</LINK>; <LINK REF="REF-Malinow-1996" TYPE="REFERENCE">Malinow 1996</LINK>; <LINK REF="REF-McCully-1996" TYPE="REFERENCE">McCully 1996</LINK>; <LINK REF="REF-Refsum-1998" TYPE="REFERENCE">Refsum 1998</LINK>; <LINK REF="REF-Taylor-1999a" TYPE="REFERENCE">Taylor 1999a</LINK>). In an analysis of 27 studies, Boushey (<LINK REF="REF-Boushey-1995" TYPE="REFERENCE">Boushey 1995</LINK>) calculated an odds ratio of 1.7 for cardiovascular disease with a 5 µmol/L increase in plasma homocysteine; 1.5 for cerebrovascular disease; whilst the odds ratio for PAD was 6.8 (though this may reflect the small number of trials looking at PAD in this study). <LINK REF="REF-Spark-2003" TYPE="REFERENCE">Spark 2003</LINK> found that homocysteine was elevated in 27% of claudicants, 50% of patients with rest pain and 53% of patients with an aortic aneurysm. A case-control study and meta-analysis reported a strong association between raised homocysteine, the MTHFR C677T mutation and PAD (<LINK REF="REF-Khandanpour-2009a" TYPE="REFERENCE">Khandanpour 2009a</LINK>). Based on experimental and clinical data it was suggested that hyperhomocysteinaemia may also be a risk factor for myointimal hyperplasia (MIH), the cause of premature restenosis and failure of peripheral bypass grafts and angioplasties (<LINK REF="REF-Currie-1996" TYPE="REFERENCE">Currie 1996</LINK>; <LINK REF="REF-Irvine-1996" TYPE="REFERENCE">Irvine 1996</LINK>; <LINK REF="REF-Iwama-1998" TYPE="REFERENCE">Iwama 1998</LINK>; <LINK REF="REF-Mireskandari-1998" TYPE="REFERENCE">Mireskandari 1998</LINK>; <LINK REF="REF-Southern-1998" TYPE="REFERENCE">Southern 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-07-14 06:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>Homocysteine provides a particularly attractive therapeutic option as blood levels of homocysteine can be easily normalised with the administration of a cheap, patient-acceptable oral vitamin treatment (<LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>) or betaine (<LINK REF="REF-Sakura-1998" TYPE="REFERENCE">Sakura 1998</LINK>; <LINK REF="REF-Wilcken-1983" TYPE="REFERENCE">Wilcken 1983</LINK>; <LINK REF="REF-Wilcken-1985" TYPE="REFERENCE">Wilcken 1985</LINK>). In a meta-analysis of 12 randomised controlled trials published by the Homocysteine Lowering Trialists' Collaboration (<LINK REF="REF-Anonymous-1998" TYPE="REFERENCE">Anonymous 1998</LINK>), a daily supplement of 0.5 to 5 mg folic acid was shown to reduce blood homocysteine levels by 25%, 0.5 mg of vitamin B12 daily reduced it by a further 7%, whilst the addition of 16.5 mg of vitamin B6 daily had no significant additional effect. It is important to note that these values are for a standardised pre-treatment plasma homocysteine concentration of 12 µmol/L (a value that many clinicians<B> </B>feel falls within the normal range) and that the reduction with vitamin treatment was greater at higher pre-treatment plasma homocysteine levels.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-04-29 15:03:05 +0100" MODIFIED_BY="[Empty name]">
<P>In vitro studies examining the pathological processes involved in atherosclerosis and restenosis have demonstrated empirical reductions in endothelial cell damage, vascular smooth muscle cell proliferation and inhibition of vasodilatation when homocysteine lowering therapies are used (<LINK REF="REF-Carmody-1999" TYPE="REFERENCE">Carmody 1999</LINK>; <LINK REF="REF-Chao-1999" TYPE="REFERENCE">Chao 1999</LINK>; <LINK REF="STD-Constans-1999" TYPE="STUDY">Constans 1999</LINK>; <LINK REF="REF-Franken-1994" TYPE="REFERENCE">Franken 1994</LINK>; <LINK REF="REF-Malinow-1998" TYPE="REFERENCE">Malinow 1998</LINK>; <LINK REF="REF-Woo-1999" TYPE="REFERENCE">Woo 1999</LINK>). However, it is unclear how these mechanisms would apply directly.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-15 09:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>PAD is a common condition and it would be potentially clinically important if outcomes could be improved by treating elevated homocysteine.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-07-14 06:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of plasma homocysteine lowering therapy on the clinical progression of disease in people with PAD and hyperhomocysteinaemia including, as a subset, those who have undergone surgical or radiological intervention.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-07-15 09:39:54 +0100" MODIFIED_BY="Karen Welch">
<SELECTION_CRITERIA MODIFIED="2013-07-15 09:39:45 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-15 09:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>Trials in which participants with PAD and hyperhomocysteinaemia were randomly allocated to either homocysteine lowering therapy or no therapy. Trials involving participants treated surgically (bypass graft, endarterectomy or thrombectomy) or radiologically (angioplasty or thrombectomy) were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-07-14 11:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Males and females of any age who had been diagnosed with PAD by an expert clinician on clinical and investigative assessment (ankle brachial index (ABI), duplex ultrasound, exercise testing, or angiography) and were found to have hyperhomocysteinaemia as measured by a blood test (as defined by &gt; 95th percentile for their control group or their local laboratory if quoted, or &gt; 11 µmol/L).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-07-14 11:56:28 +0100" MODIFIED_BY="[Empty name]">
<P>Trials using any therapy where the purpose was specifically to lower plasma homocysteine levels, but in particular folic acid, vitamin B12, vitamin B6, and betaine.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-07-14 11:58:41 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-07-14 11:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>The following primary outcomes were considered:</P>
<UL>
<LI>death;</LI>
<LI>limb loss rate;</LI>
<LI>changes in the ankle brachial index (ABI).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-14 11:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>The following secondary outcomes were considered:</P>
<UL>
<LI>cardiovascular death;</LI>
<LI>number of defined cardiovascular events;</LI>
<LI>changes in walking distance and maximum walking distance on treadmill exercise;</LI>
<LI>grading of patency on duplex scanning or angiography;</LI>
<LI>failure of treatment;</LI>
<LI>graft restenosis in those with graft disease;</LI>
<LI>time to failure of treatment;</LI>
<LI>quality of life assessments.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-07-14 12:03:15 +0100" MODIFIED_BY="Karen Welch">
<P>We did not apply any language restrictions on publications or any restrictions regarding publications status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-07-14 12:03:15 +0100" MODIFIED_BY="Karen Welch">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched January 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 12), part of <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases (PVD) Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>The following trial databases were searched by the TSC (January 2013) for details of ongoing and unpublished studies using the term homocysteine:</P>
<UL>
<LI>World Health Organization International Clinical Trials Registry (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-14 12:02:03 +0100" MODIFIED_BY="Karen Welch">
<P>The reference lists of relevant articles retrieved by the electronic searches were searched for additional citations. We also contacted the study authors for further information when the data were missing or we were unsure whether to include trials in the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-15 09:39:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2013-04-08 11:19:54 +0100" MODIFIED_BY="[Empty name]">
<P>The selection of trials for inclusion in the review was carried out by two review authors (AA,GS). Authors of trials were contacted for further information.</P>
<P>We obtained full versions of articles that potentially met the inclusion criteria based on the title or abstract and assessed these independently against the inclusion criteria. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-07-14 12:02:58 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, GS) independently extracted data using the proformas available in the PVD Group. Any information that was absent in the publications was sought directly from the study authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-14 12:04:11 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, GS) independently performed an assessment of methodological quality using the risk of bias tool from The Cochrane Colllaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed the following domains: selection bias, performance and detection bias, attrition bias, reporting bias, and other source of bias. We allocated a judgement of high risk of bias, low risk of bias, or unclear risk of bias according to the guidelines from the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-05-13 12:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform statistical analysis using RevMan 5.2 according to the statistical guidelines for review authors in the Cochrane PVD Group. We planned to use odds ratio (OR) with 95% confidence interval (CI) for dichotomous outcomes, and mean difference (MD) with 95% CI for continuous outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-02-07 12:52:51 +0000" MODIFIED_BY="[Empty name]">
<P>Participating individuals were the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-02-07 12:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of trials to clarify data and provide missing values.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-14 12:06:44 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to conduct an intention-to-treat analysis. Heterogeneity would be assessed using the Chi<SUP>2</SUP> test of heterogeneity and I<SUP>2</SUP> statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). The reason for the heterogeneity would be investigated if heterogeneity was identified (P &lt; 0.1 or I<SUP>2</SUP> &gt; 50%). A random-effects model meta-analysis would be conducted if no reason for the heterogeneity was found. A fixed-effect model would be used in the absence of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-14 12:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use asymmetry in the funnel plots to assess reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-14 12:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>If sufficient trials were available, we planned to pool trial results by meta-analysis.</P>
<P>Calculated ORs from the individual trials would be combined across trials in order to assign weight to the number of events in each of the two treatment groups in each separate trial, using the Mantel-Haenszel procedure for assumed fixed treatment effect (<LINK REF="REF-Collins-1987" TYPE="REFERENCE">Collins 1987</LINK>; <LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>). We planned to use a random-effects model where clinical or statistical heterogeneity existed (P &lt; 0.1 or I<SUP>2</SUP> &gt; 50%). If the heterogeneity was absent, we planned to use a fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-14 12:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform separate analyses of the various homocysteine lowering treatments versus placebo. Homocysteine lowering treatments considered for this review were folic acid, vitamin B12, vitamin B6, betaine or any other relevant therapy. We also planned to perform a subgroup analysis for the subset who had undergone surgical or radiological interventions.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-07-15 09:39:54 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform a primary analysis that included data from all participants in the trials during the period of randomly allocated treatment.</P>
<P>We planned to perform a sensitivity analysis to assess the effect of trials with low methodological quality.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-07-15 09:40:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-07-15 09:40:50 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2013-07-14 12:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>For this update we identified two new included studies and three new excluded studies.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-14 12:17:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials were included in this review. The description of these trials (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>; <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>) is presented in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. </P>
<P>
<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> was a randomised controlled trial investigating whether folate supplementation improved arterial function in participants with PAD, with participants randomly assigned to receive 400 µg folic acid (n = 46), 5-methyltetrahydrofolate (5-MTHF) (n = 51) or placebo (n = 46) for 16 weeks. <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK> was a randomised controlled trial examining the role of oral treatment with B vitamins in normalising endothelium-dependant, flow-dependent vasodilation in participants with peripheral arterial occlusive disease and hyperhomocysteinaemia; the participants were assigned to oral treatment with combined B vitamins (10 mg folate, 200 µg vitamin B12, and 20 mg vitamin B6 per day) (n = 9) or placebo (n = 9) for eight weeks.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-07-15 09:40:50 +0100" MODIFIED_BY="[Empty name]">
<P>For this update three additional studies were excluded (<LINK REF="STD-Carrero-2005" TYPE="STUDY">Carrero 2005</LINK>; <LINK REF="STD-Lonn-2006" TYPE="STUDY">Lonn 2006</LINK>; <LINK REF="STD-Taylor-1999" TYPE="STUDY">Taylor 1999</LINK>), making a total of six excluded studies. The reasons for exclusion were as follows.</P>
<UL>
<LI>Non-randomised trials:</LI>
<UL>
<LI>
<LINK REF="STD-Constans-1999" TYPE="STUDY">Constans 1999</LINK>, a small study of 18 participants with cardiovascular disease and hyperhomocysteinaemia, which included nine participants with PAD;</LI>
<LI>
<LINK REF="STD-De-Jong-1999" TYPE="STUDY">De Jong 1999</LINK>, 70 participants with hyperhomocysteinaemia who were treated with 5 mg/day folic acid plus 250 mg/day vitamin B6.</LI>
</UL>
</UL>
<UL>
<LI>Non-specific to lower plasma homocysteine:</LI>
<UL>
<LI>
<LINK REF="STD-Carrero-2005" TYPE="STUDY">Carrero 2005</LINK>, a dietary intervention of fortified dairy products combined with increased consumption of fruit, legumes and vegetables;</LI>
<LI>
<LINK REF="STD-Garg-1999" TYPE="STUDY">Garg 1999</LINK>, which looked at the effect of niacin treatment on lowering plasma lipids and additionally on plasma homocysteine levels.</LI>
</UL>
</UL>
<UL>
<LI>Participants with PAD were not reported as a separate group:</LI>
</UL>
<UL>
<UL>
<LI>
<LINK REF="STD-Lonn-2006" TYPE="STUDY">Lonn 2006</LINK>, a randomised controlled trial of participants with vascular disease or diabetes, treated daily with 2.5 mg of folic acid, 50 mg of vitamin B6 and 1 mg of vitamin B12 versus placebo;</LI>
<LI>
<LINK REF="STD-Taylor-1999" TYPE="STUDY">Taylor 1999</LINK>, a blinded prospective randomised placebo-controlled trial of folic acid (4 mg/day) treatment in participants with symptomatic lower extremity and cerebrovascular disease.</LI>
</UL>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-14 12:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>The details for the risk of bias assessments are described in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and are summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-07-14 12:31:15 +0100" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> the method used to generate the allocation sequence was described as a randomly generated list by computer software, indicating a low risk of bias.The randomisation was organised independently and the pharmacist had no contact with participants or trial coordinators. <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK> used a pharmacist to randomise and label the medication, but the sequence generation and allocation concealment were not described so the risk of bias was judged to be unclear for this trial.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-07-14 12:31:35 +0100" MODIFIED_BY="[Empty name]">
<P>One of the included trials (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>) was at unclear risk of bias for performance and detection bias because the blinding procedures were not specified in the publication. The risk of bias was rated low in the other trial (<LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>) as the randomisation was performed by a pharmacist and the randomisation codes were concealed from the investigators.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-07-14 12:32:03 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias was low for both trials (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>; <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>) as the studies followed up and reported on all of the participants.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-04-19 08:52:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> and <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK> were deemed to be at low risk of reporting bias as all planned outcomes were reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-07-14 12:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>Both trials (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>; <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>) were deemed free of other sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-15 09:39:58 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analyses and forest plots were not provided, and investigations for heterogeneity and reporting bias, subgroup analyses, and sensitivity analyses were not carried out as the two included trials had different interventions: folic acid and 5-MTHF (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>), and vitamin B supplementation with folate, vitamin B12 and vitamin B6 (<LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>The primary outcomes death and limb loss rate were not described by either <LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> or <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Changes in ankle brachial index (ABI)</HEADING>
<P>
<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> reported changes in ABI. The trial showed that there was a significant improvement in ABI in participants who received folic acid versus placebo (MD 0.07, 95% CI 0.04 to 0.11, P &lt; 0.001) and in participants who received 5-MTHF versus placebo (MD 0.05, 95% CI 0.01 to 0.10, P = 0.009).</P>
<P>Oral treatment with B vitamins for eight weeks (<LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>) had no impact on the ABI (P stated as non-significant) in participants with occlusive PAD, stable intermittent claudication, elevated homocysteine levels and stable medication (mean ± SEM: 0.7 ± 0.1) compared with the placebo group (mean ± SEM: 0.8 ± 0.1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>It was stated by <LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> that no major events occurred during the study, but no further details were given. <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK> did not report on side effects. No other information on the planned secondary outcomes for this review were reported by <LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> and <LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-07-15 09:43:08 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-07-14 12:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>This updated review of homocysteine lowering interventions for peripheral arterial disease (PAD) and bypass grafts identified two randomised controlled trials with a total of 161 participants. One of the trials, with 143 participants, reported that folate treatment may improve the ABI in participants with PAD, while the second trial of 18 participants found no differences in the ABI of participants treated with B vitamins. No major events were reported and no other information on clinical endpoints was available.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-07-14 12:47:18 +0100" MODIFIED_BY="[Empty name]">
<P>As only two trials were included in this review comparing different homocysteine lowering therapies with placebo, and they provided information only on ABI, the data cannot be generalised to the wider population.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-07-14 12:48:15 +0100" MODIFIED_BY="[Empty name]">
<P>The trials included in this review were randomised double-blind placebo-controlled trials. Blinding of personnel and outcome assessors was undertaken by one trial (<LINK REF="STD-Sydow-2003" TYPE="STUDY">Sydow 2003</LINK>). Allocation was generated by using a computer generated list in one trial (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-07-14 12:54:28 +0100" MODIFIED_BY="[Empty name]">
<P>The methods used to conduct the review are described in detail in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), in particular the independent application of the review eligibility criteria, independent data extraction and assessment of the risk of bias. The Cochrane PVD Group Trials Search Co-ordinator devised and conducted the search strategies. The potential biases in the review process are the way the data were presented in the included trials. <LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK> included participants with high levels of homocysteine at baseline (median value 13.31 µmol/L, interquartile range 10.83 to 15.55 µmol/L) (n = 133) but did not specifically recruit participants with homocysteine levels higher than 11 µmol/L. In addition, they did not separately analyse participants with homocysteine levels higher than 11 µmol/L.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-07-15 09:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>There are several studies and trials available which have confirmed the reduction of plasma homocysteine levels using folic acid, vitamin B12, vitamin B6 or betaine, alone or in combination, in healthy volunteers or in patients presenting with venous thrombosis (<LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>). However, as these trials were based on healthy volunteers or patients presenting with venous thrombosis they did not meet the inclusion criteria of this review.</P>
<P>In a non-randomised trial, De Jong (<LINK REF="STD-De-Jong-1999" TYPE="STUDY">De Jong 1999</LINK>) followed 232 patients with PAD of whom 70% had normal homocysteine levels and 30% had hyperhomocysteinaemia, which they treated with vitamin supplements (5 mg/day folic acid plus 250 mg/day vitamin B6). <LINK REF="STD-De-Jong-1999" TYPE="STUDY">De Jong 1999</LINK> demonstrated that vitamin treatment significantly reduced plasma homocysteine concentrations and further suggested that the incidence of a new cardiovascular event was reduced in the hyperhomocysteinaemic group treated with vitamins to that of the group with normal homocysteine levels. Another study (<LINK REF="REF-Vermeulen-2000" TYPE="REFERENCE">Vermeulen 2000</LINK>) demonstrated that vitamin treatment with 5 mg/day folic acid plus 250 mg/day vitamin B6 for two years in 78 healthy siblings of patients with early onset atherothrombotic disease reduced fasting homocysteine concentrations and was associated with a decreased rate of abnormal exercise electrocardiography tests. However, there was no apparent effect of vitamin treatment on ABI or on carotid or femoral patency. Another study of asymptomatic occlusive vascular disease adults with hyperhomocysteinaemia treated with folic acid 10 mg/day for eight weeks demonstrated a significant improvement in endothelium-dependant dilatation of the brachial artery (8.2% <U>+</U> 1.6% versus 6.0% <U>+</U> 1.3%, P &lt; 0.001) (<LINK REF="REF-Woo-1999" TYPE="REFERENCE">Woo 1999</LINK>). These studies suggest that vitamin treatment may improve peripheral arterial outcomes. However, without evidence from well conducted large randomised trials these results must be viewed with caution.</P>
<P>In one of the excluded randomised trials (<LINK REF="STD-Garg-1999" TYPE="STUDY">Garg 1999</LINK>), the purpose of niacin treatment was to lower plasma lipids. With increasing evidence of the role of hyperhomocysteinaemia in PAD, the trialists extended their investigation to use a subset of patients and analyse the effect of the vitamin on plasma homocysteine concentrations. Niacin is not a drug commonly used for the treatment of hyperhomocysteinaemia and therefore the result that niacin in fact increases plasma homocysteine levels is not extraordinary. This was a small study (52 patients) but, based on these results, clinicians should be aware that in lowering lipids using niacin they could potentially be increasing the effects of another risk factor. The authors of the trial have recommended the initiation of a further study looking at a combination of niacin and homocysteine lowering treatment in patients with PAD.</P>
<P>Daily supplementation for one year with fortified daily products containing folic acid and vitamin B6 was shown to increase ABI and pain free walking distance in a trial (<LINK REF="STD-Carrero-2005" TYPE="STUDY">Carrero 2005</LINK>) involving a small group (30 patients) prescribed an antiplatelet agent (trifusal) and a haemorrheologic agent (pentoxifylline).</P>
<P>One systematic review and meta-analysis (<LINK REF="REF-Khandanpour-2009b" TYPE="REFERENCE">Khandanpour 2009b</LINK>) evaluated the homocysteine levels in patients with PAD and reviewed the clinical effects of the therapy. The review authors recognised that they were not able to conduct a meta-analysis on major clinical endpoints such as need for amputation as they could not identify well designed trials suitable for such an analysis. They did not include in the review their own double-blinded randomised controlled trial assessing the outcomes of folic acid supplementation on clinical signs of PAD (<LINK REF="STD-Khandanpour-2009" TYPE="STUDY">Khandanpour 2009</LINK>) and concluded that there is little published evidence on the effects of folate supplementation on major clinical outcomes relating to PAD.</P>
<P>Another meta-analysis looked at the effect of homocysteine interventions on the risk of cardiocerebrovascular events (<LINK REF="REF-Mei-2010" TYPE="REFERENCE">Mei 2010</LINK>). The authors concluded that folic acid is not effective in the secondary prevention of cardiovascular disease in patients with a history of vascular disease. Similarly, a Cochrane review assessed the clinical effectiveness of homocysteine lowering interventions in people with or without pre-existing cardiovascular disease (<LINK REF="REF-Marti_x002d_Carvajal-2013" TYPE="REFERENCE">Marti-Carvajal 2013</LINK>). Supplements of vitamins B6, B9 and B12, given alone or in combination, were used as homocysteine lowering interventions and they did not prevent cardiovascular events.</P>
<P>A review of the design and power of large randomised trials of homocysteine lowering interventions for prevention of cardiovascular events (<LINK REF="REF-Anonymous-2006" TYPE="REFERENCE">Anonymous 2006</LINK>) acknowledged the need for larger trials with extended treatment duration, which would have sufficient power to detect plausible differences in risk at considerable significant levels. The authors suggested that the trials should have a statistical power dependant on a series a factors such as number of vascular events, difference between the B vitamin-treated and control groups, and various risks associated with homocysteine concentrations, speed of risk reversal and trial duration.</P>
<P>Treatment of the effects of PAD, and subsequent treatment for the failure of such interventions, involves a large section of our community and produces a huge burden on the National Health Service (NHS) in the UK. Any measures to inhibit progression of the disease and delay the need for intervention, and to decrease further the requirement for re-intervention, could potentially have a considerable impact on modern hospital practice. Hyperhomocysteinaemia has been shown to be an independent risk factor for the progression of PAD. Measurement of plasma levels of homocysteine is now widely available, and studies in healthy people have demonstrated that treatment with B vitamins in particular can effectively and safely reduce plasma homocysteine to normal levels. However, the effect of such treatment in patients with PAD and those undergoing surgical or radiological intervention is currently unknown. Large trials of folic acid, vitamin B12, vitamin B6 and betaine, alone or in combination, in patients with PAD are urgently required.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-14 13:21:43 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-07-14 13:21:18 +0100" MODIFIED_BY="[Empty name]">
<P>There is a lack of data about the effects of treating elevated plasma homocysteine levels on progression and outcomes for people with peripheral arterial disease (PAD) and hyperhomocysteinaemia. Currently there is insufficient evidence to recommend the use of homocysteine lowering treatment in PAD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-14 13:21:43 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for further randomised controlled trials, with adequate sample size and clinically appropriate outcomes, assessing the effects of plasma homocysteine lowering therapy on the clinical progression of disease in people with PAD and hyperhomocysteinaemia.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-07-14 06:55:08 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank the Cochrane Consumer Network for providing the plain language summary.</P>
<P>We would also like to thank the personnel from the Cochrane Peripheral Vascular Disease Review Group, especially Marlene Stewart and Karen Welch for their invaluable support and advice.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-04-08 11:31:16 +0100" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-04-29 15:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>A Andras (AA): assessment of eligibility of trials, extraction of data and analysis, writing of review update<BR/>G Stansby (GS): assessment of eligibility of trials, extraction of data, critical review, writing of review update<BR/>M Hansrani (MH): critical review and contributed to the review text</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-05-13 12:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of the methodological quality of the included trials was changed to the Cochrane Collaboration's recommended 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-07-14 06:52:28 +0100" MODIFIED_BY="Karen Welch">
<STUDIES MODIFIED="2013-07-14 06:44:17 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Khandanpour-2009" MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Khandanpour 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khandanpour N, Armon MP, Jennings B, Finglas PM, Willis G, Clark A, et al</AU>
<TI>Randomized clinical trial of folate supplementation in patients with peripheral arterial disease</TI>
<SO>British Journal of Surgery</SO>
<YR>2009</YR>
<VL>96</VL>
<NO>9</NO>
<PG>990-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-13 08:45:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Khandanpour N, Armon MP, Jennings B, Willis G, Clark A, Meyer FJ</AU>
<TI>Folate supplementation improves arterial function in patients with peripheral arterial disease: a randomised double-blind, placebo-controlled clinical trial</TI>
<SO>The Vascular Society of Great Britain &amp; Ireland Yearbook 2008</SO>
<YR>2008</YR>
<PG>81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sydow-2003" MODIFIED="2013-05-13 08:46:45 +0100" MODIFIED_BY="[Empty name]" NAME="Sydow 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-13 08:46:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, et al</AU>
<TI>ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins</TI>
<SO>Cardiovascular Research</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>1</NO>
<PG>244-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-07-14 06:44:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carrero-2005" MODIFIED="2013-05-13 08:56:46 +0100" MODIFIED_BY="[Empty name]" NAME="Carrero 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-13 08:56:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrero JJ, López-Huertas E, Salmerón LM, Baró L, Ros E</AU>
<TI>Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease</TI>
<SO>The Journal of Nutrition</SO>
<YR>2005</YR>
<VL>135</VL>
<NO>6</NO>
<PG>1393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Constans-1999" MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Constans 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Constans J, Blann AD, Resplandy F, Parrot F, Renard M, Seigneur M, et al</AU>
<TI>Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction</TI>
<SO>British Journal of Haematology</SO>
<YR>1999</YR>
<VL>107</VL>
<NO>4</NO>
<PG>776-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jong-1999" NAME="De Jong 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM, Rauwerda JA</AU>
<TI>Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1999</YR>
<VL>246</VL>
<NO>1</NO>
<PG>87-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-1999" MODIFIED="2013-05-13 09:00:50 +0100" MODIFIED_BY="[Empty name]" NAME="Garg 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-05-13 09:00:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D</AU>
<TI>Niacin treatment increases plasma homocyst(e)ine levels</TI>
<SO>American Heart Journal</SO>
<YR>1999</YR>
<VL>138</VL>
<NO>6 Part 1</NO>
<PG>1082-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonn-2006" MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Lonn 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-13 13:16:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators</AU>
<TI>Homocysteine lowering with folic acid and B vitamins in vascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>15</NO>
<PG>1567-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Taylor-1999" MODIFIED="2013-07-14 06:44:17 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 1999" YEAR="2006">
<REFERENCE MODIFIED="2013-05-13 12:33:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>Homocysteine and progression of atherosclerosis</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00005338 (accessed 1 May 2013)</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ClinicalTrials.gov Identifier: NCT00005338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-13 09:15:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musicant SE, Taylor LM Jr, Peters D, Schuff RA, Urankar R, Landry GJ, et al</AU>
<TI>Prospective evaluation of the relationship of between C-reactive protein, D-dimer and progression of peripheral arterial disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>4</NO>
<PG>772-80, discussion 780</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-14 06:44:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicoloff AD, Taylor JM Jr, Sexton GJ, Schuff RA, Edwards JMM, Yeager RA, et al; Homocysteine and Progression of Atherosclerosis Study Investigators</AU>
<TI>Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1</NO>
<PG>38-46, discussion 46-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-14 06:44:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM</AU>
<TI>Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>1</NO>
<PG>8-19, discussion 19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-05-07 09:36:53 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-03-06 10:46:41 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-07-14 06:52:28 +0100" MODIFIED_BY="Karen Welch">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-14 06:52:28 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-2005" MODIFIED="2013-07-05 08:48:19 +0100" MODIFIED_BY="[Empty name]" NAME="Adam 2005" TYPE="JOURNAL_ARTICLE">
<AU>Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al</AU>
<TI>Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9501</NO>
<PG>1925-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1998" MODIFIED="2013-05-13 09:21:39 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1998" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7135</NO>
<PG>894-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2006" MODIFIED="2013-05-13 09:22:41 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2006" TYPE="JOURNAL_ARTICLE">
<AU>B-Vitamin Treatment Trialists' Collaboration</AU>
<TI>Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>151</VL>
<NO>2</NO>
<PG>282-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bainton-1994" MODIFIED="2008-10-16 12:51:00 +0100" MODIFIED_BY="[Empty name]" NAME="Bainton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bainton D, Sweetnam P, Baker I, Elwood P</AU>
<TI>Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study</TI>
<SO>British Heart Journal</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>2</NO>
<PG>128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boushey-1995" MODIFIED="2008-10-16 12:51:09 +0100" MODIFIED_BY="[Empty name]" NAME="Boushey 1995" TYPE="JOURNAL_ARTICLE">
<AU>Boushey CJ, Beresford SA, Omenn GS, Motulsky AG</AU>
<TI>A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>13</NO>
<PG>1049-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carmody-1999" MODIFIED="2013-05-13 09:26:47 +0100" MODIFIED_BY="[Empty name]" NAME="Carmody 1999" TYPE="JOURNAL_ARTICLE">
<AU>Carmody BJ, Arora S, Avena R, Cosby K, Sidawy AN</AU>
<TI>Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1121-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cattaneo-1999" MODIFIED="2013-05-13 12:34:20 +0100" MODIFIED_BY="[Empty name]" NAME="Cattaneo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cattaneo M</AU>
<TI>Hyperhomocysteinemia, atherosclerosis and thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>2</NO>
<PG>165-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chao-1999" MODIFIED="2008-10-16 12:51:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chao 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chao CL, Chien KL, Lee YT</AU>
<TI>Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>11</NO>
<PG>1359-61, A8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1991" MODIFIED="2008-10-16 12:51:41 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al</AU>
<TI>Hyperhomocysteinemia: an independent risk factor for vascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>17</NO>
<PG>1149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1998" MODIFIED="2008-10-16 12:51:32 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM</AU>
<TI>Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>11</NO>
<PG>1449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1987" MODIFIED="2013-03-12 15:10:34 +0000" MODIFIED_BY="[Empty name]" NAME="Collins 1987" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Gray R, Godwin J, Peto R</AU>
<TI>Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coni-1992" MODIFIED="2008-10-16 12:51:46 +0100" MODIFIED_BY="[Empty name]" NAME="Coni 1992" TYPE="JOURNAL_ARTICLE">
<AU>Coni N, Tennison B, Troup M</AU>
<TI>Prevalence of lower extremity arterial disease among elderly people in the community</TI>
<SO>British Journal of General Practice</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>357</NO>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Criqui-1997" MODIFIED="2008-10-16 12:51:56 +0100" MODIFIED_BY="[Empty name]" NAME="Criqui 1997" TYPE="JOURNAL_ARTICLE">
<AU>Criqui MH, Denenberg JO, Langer RD, Fronek A</AU>
<TI>The epidemiology of peripheral arterial disease: importance of identifying the population at risk</TI>
<SO>Vascular Medicine</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>3</NO>
<PG>221-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Currie-1996" MODIFIED="2013-05-13 09:34:37 +0100" MODIFIED_BY="[Empty name]" NAME="Currie 1996" TYPE="JOURNAL_ARTICLE">
<AU>Currie IC, Wilson YG, Scott J, Day A, Stansbie D, Baird RN, et al</AU>
<TI>Homocysteine:an independant risk factor for the failure of vascular intervention</TI>
<SO>British Journal of Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>9</NO>
<PG>1238-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-den-Heijer-1998" MODIFIED="2013-05-13 12:34:35 +0100" MODIFIED_BY="[Empty name]" NAME="den Heijer 1998" TYPE="JOURNAL_ARTICLE">
<AU>den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM</AU>
<TI>Hyperhomocysteinemia and venous thrombosis: a meta-analysis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>6</NO>
<PG>874-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diehm-2004" MODIFIED="2013-07-05 08:49:01 +0100" MODIFIED_BY="[Empty name]" NAME="Diehm 2004" TYPE="JOURNAL_ARTICLE">
<AU>Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al</AU>
<TI>High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study</TI>
<SO>Atherosclerosis</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>1</NO>
<PG>95-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dormandy-1991" MODIFIED="2008-10-16 12:52:02 +0100" MODIFIED_BY="[Empty name]" NAME="Dormandy 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dormandy JA, Murray GD</AU>
<TI>The fate of the claudicant -- a prospective study of 1969 claudicants</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>2</NO>
<PG>131-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franken-1994" MODIFIED="2013-05-13 12:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Franken 1994" TYPE="JOURNAL_ARTICLE">
<AU>Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW</AU>
<TI>Treatment of mild hyperhomocysteinemia in vascular disease patients</TI>
<SO>Arteriosclerosis and Thrombosis</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>3</NO>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hermans-1992" MODIFIED="2013-05-13 09:38:52 +0100" MODIFIED_BY="[Empty name]" NAME="Hermans 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hermans WR, Rensing BJ, Foley DP, Deckers JW, Rutsch W, Emanuelsson H, et al</AU>
<TI>Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>4</NO>
<PG>767-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-05-13 09:40:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hooi-2001" MODIFIED="2013-05-13 09:42:30 +0100" MODIFIED_BY="[Empty name]" NAME="Hooi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hooi JD, Kester ADM, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA</AU>
<TI>Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2001</YR>
<VL>153</VL>
<NO>7</NO>
<PG>666-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inglis-2013" MODIFIED="2013-07-05 08:49:25 +0100" MODIFIED_BY="[Empty name]" NAME="Inglis 2013" TYPE="JOURNAL_ARTICLE">
<AU>Inglis SC, Hermis A, Shehab S, Newton PJ, Lal S, Davidson PM</AU>
<TI>Peripheral arterial disease and chronic heart failure: a dangerous mix</TI>
<SO>Heart Failure Reviews</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>4</NO>
<PG>457-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irvine-1996" MODIFIED="2008-10-16 12:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Irvine 1996" TYPE="JOURNAL_ARTICLE">
<AU>Irvine C, Wilson YG, Currie IC, McGrath C, Scott J, Day A, et al</AU>
<TI>Hyperhomocysteinaemia is a risk factor for vein graft stenosis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>304-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iwama-1998" MODIFIED="2008-10-16 12:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="Iwama 1998" TYPE="JOURNAL_ARTICLE">
<AU>Iwama Y, Mokuno H, Yokoi H, Daida H, Yamaguchi H, Hosoda Y</AU>
<TI>[Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery]</TI>
<SO>Journal of Cardiology</SO>
<YR>1998 Dec</YR>
<VL>32</VL>
<NO>6</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khandanpour-2009a" MODIFIED="2013-05-13 09:47:00 +0100" MODIFIED_BY="[Empty name]" NAME="Khandanpour 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, et al</AU>
<TI>Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>3</NO>
<PG>711-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khandanpour-2009b" MODIFIED="2013-07-14 06:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Khandanpour 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP</AU>
<TI>Homocysteine and peripheral arterial disease: systematic review and meta-analysis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>3</NO>
<PG>316-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leng-1996" MODIFIED="2008-10-16 12:52:39 +0100" MODIFIED_BY="[Empty name]" NAME="Leng 1996" TYPE="JOURNAL_ARTICLE">
<AU>Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al</AU>
<TI>Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1172-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malinow-1996" MODIFIED="2008-10-16 12:52:43 +0100" MODIFIED_BY="[Empty name]" NAME="Malinow 1996" TYPE="JOURNAL_ARTICLE">
<AU>Malinow MR</AU>
<TI>Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases</TI>
<SO>Journal of Nutrition</SO>
<YR>1996</YR>
<VL>126</VL>
<NO>4 Suppl</NO>
<PG>1238S-43S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malinow-1998" MODIFIED="2008-10-16 12:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Malinow 1998" TYPE="JOURNAL_ARTICLE">
<AU>Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al</AU>
<TI>Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>15</NO>
<PG>1009-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" MODIFIED="2013-03-07 11:49:28 +0000" MODIFIED_BY="[Empty name]" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective studies of disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<NO>4</NO>
<PG>719-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marti_x002d_Carvajal-2013" MODIFIED="2013-04-29 11:04:53 +0100" MODIFIED_BY="[Empty name]" NAME="Marti-Carvajal 2013" TYPE="COCHRANE_REVIEW">
<AU>Marti-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D</AU>
<TI>Homocysteine-lowering interventions for preventing cardiovascular events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-04-29 11:03:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-29 11:03:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006612.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCully-1969" MODIFIED="2008-10-16 12:52:49 +0100" MODIFIED_BY="[Empty name]" NAME="McCully 1969" TYPE="JOURNAL_ARTICLE">
<AU>McCully KS</AU>
<TI>Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis</TI>
<SO>American Journal of Pathology</SO>
<YR>1969</YR>
<VL>56</VL>
<NO>1</NO>
<PG>111-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCully-1996" MODIFIED="2008-10-16 12:52:54 +0100" MODIFIED_BY="[Empty name]" NAME="McCully 1996" TYPE="JOURNAL_ARTICLE">
<AU>McCully KS</AU>
<TI>Homocysteine and vascular disease</TI>
<SO>Nature Medicine</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>386-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mei-2010" MODIFIED="2013-05-13 09:56:53 +0100" MODIFIED_BY="[Empty name]" NAME="Mei 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mei W, Rong Y, Jinming L, Yongjun L, Hui Z</AU>
<TI>Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials</TI>
<SO>International Journal of Clinincal Practice</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meijer-1998" MODIFIED="2008-10-16 12:53:08 +0100" MODIFIED_BY="[Empty name]" NAME="Meijer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE</AU>
<TI>Peripheral arterial disease in the elderly: The Rotterdam Study</TI>
<SO>Arteriosclerosis, Thrombosis, and Vascular Biology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mireskandari-1998" MODIFIED="2013-07-14 06:50:47 +0100" MODIFIED_BY="[Empty name]" NAME="Mireskandari 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mireskandari M, Schachter M, Timms IGO, Sever P, Wolfe JHN</AU>
<TI>Plasma homocysteine is an independent risk factor for vein graft stenosis</TI>
<SO>British Journal of Surgery</SO>
<YR>1998</YR>
<VL>85 Suppl</VL>
<NO>Supp 1</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2012" MODIFIED="2013-07-14 06:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2012" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Lower limb peripheral arterial disease: diagnosis and management</TI>
<SO>http://guidance.nice.org.uk/CG147/NICEGuidance/pdf/English</SO>
<YR>August 2012 (accessed 4 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pell-1994" MODIFIED="2008-10-16 12:53:01 +0100" MODIFIED_BY="[Empty name]" NAME="Pell 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pell JP, Whyman MR, Fowkes FG, Gillespie I, Ruckley CV</AU>
<TI>Trends in vascular surgery since the introduction of percutaneous transluminal angioplasty</TI>
<SO>British Journal of Surgery</SO>
<YR>1994</YR>
<VL>81</VL>
<NO>6</NO>
<PG>832-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Refsum-1998" MODIFIED="2008-10-16 12:53:04 +0100" MODIFIED_BY="[Empty name]" NAME="Refsum 1998" TYPE="JOURNAL_ARTICLE">
<AU>Refsum H, Ueland PM, Nygard O, Vollset SE</AU>
<TI>Homocysteine and cardiovascular disease</TI>
<SO>Annual Review of Medicine</SO>
<YR>1998</YR>
<VL>49</VL>
<PG>31-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sakura-1998" MODIFIED="2008-10-16 12:53:13 +0100" MODIFIED_BY="[Empty name]" NAME="Sakura 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sakura N, Ono H, Nomura S, Ueda H, Fujita N</AU>
<TI>Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>1</NO>
<PG>84-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shammas-2007" MODIFIED="2013-07-05 08:52:32 +0100" MODIFIED_BY="[Empty name]" NAME="Shammas 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shammas NW</AU>
<TI>Epidemiology, classification, and modifiable risk factors of peripheral arterial disease</TI>
<SO>Vascular Health and Risk Management</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>2</NO>
<PG>229-34</PG>
<IDENTIFIERS MODIFIED="2013-07-04 13:51:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Southern-1998" MODIFIED="2008-10-16 12:53:20 +0100" MODIFIED_BY="[Empty name]" NAME="Southern 1998" TYPE="JOURNAL_ARTICLE">
<AU>Southern FN, Cruz N, Fink LM, Cooney CA, Barone GW, Eidt JF, et al</AU>
<TI>Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>5</NO>
<PG>909-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spark-2003" MODIFIED="2013-05-13 10:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Spark 2003" TYPE="JOURNAL_ARTICLE">
<AU>Spark JI, Laws P, Fitridge R</AU>
<TI>The incidence of hyperhomocysteinaemia in vascular patients</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>5</NO>
<PG>558-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoffers-1996" MODIFIED="2013-05-13 10:46:17 +0100" MODIFIED_BY="[Empty name]" NAME="Stoffers 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA</AU>
<TI>The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>2</NO>
<PG>282-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoyioglou-2004" MODIFIED="2013-07-05 08:53:07 +0100" MODIFIED_BY="[Empty name]" NAME="Stoyioglou 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stoyioglou A, Jaff MR</AU>
<TI>Medical treatment of peripheral arterial disease: a comprehensive review</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1197-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1999a" MODIFIED="2013-07-14 06:52:28 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM</AU>
<TI>Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>1</NO>
<PG>8-19, discussion 19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1994" MODIFIED="2013-05-13 10:51:46 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thompson MM, Budd JS, Eady SL, Underwood MJ, James RFL, Bell PRF</AU>
<TI>The effect of transluminal endothelial seeding on myointimal hyperplasia following angioplasty</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>4</NO>
<PG>423-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2000" MODIFIED="2013-05-13 10:54:23 +0100" MODIFIED_BY="[Empty name]" NAME="Tierney 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tierney S, Fennessy F, Hayes DB</AU>
<TI>ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>320</VL>
<NO>7244</NO>
<PG>1262-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verin-1995" MODIFIED="2013-05-13 10:54:50 +0100" MODIFIED_BY="[Empty name]" NAME="Verin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Verin V, Popowski Y, Urban P, Belenger J, Redard M, Costa M, et al</AU>
<TI>Intra-arterial beta irradiation prevents neointimal hyperplasia in a hypercholesterolemic rabbit restenosis model</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>8</NO>
<PG>2284-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-2000" MODIFIED="2013-05-13 10:58:55 +0100" MODIFIED_BY="[Empty name]" NAME="Vermeulen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen EG, Stehouwer CD, Twisk JW, van der Berg M, De Jong SC, Mackaay AJ, et al</AU>
<TI>Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9203</NO>
<PG>517-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Voller-2002" MODIFIED="2013-07-05 08:53:43 +0100" MODIFIED_BY="[Empty name]" NAME="Voller 2002" TYPE="JOURNAL_ARTICLE">
<AU>Voller H</AU>
<TI>Peripheral arterial disease (PAD): secondary prevention</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>2002</YR>
<VL>127</VL>
<NO>37</NO>
<PG>1870-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2007" MODIFIED="2013-07-05 08:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="White 2007" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Gray WA</AU>
<TI>Endovascular therapies for peripheral arterial disease: an evidence-based review</TI>
<SO>Circulation</SO>
<YR>2007</YR>
<VL>116</VL>
<NO>19</NO>
<PG>2203-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilcken-1983" MODIFIED="2013-05-13 10:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Wilcken 1983" TYPE="JOURNAL_ARTICLE">
<AU>Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA</AU>
<TI>Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>8</NO>
<PG>448-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilcken-1985" MODIFIED="2013-05-13 11:02:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wilcken 1985" TYPE="JOURNAL_ARTICLE">
<AU>Wilcken DE, Dudman NP, Tyrrell PA</AU>
<TI>Homocystinuria due to cystathionine beta-synthase deficiency--the effects of betaine treatment in pyridoxine-responsive patients</TI>
<SO>Metabolism</SO>
<YR>1985</YR>
<VL>34</VL>
<NO>12</NO>
<PG>1115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woo-1999" MODIFIED="2008-10-16 12:54:05 +0100" MODIFIED_BY="[Empty name]" NAME="Woo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS</AU>
<TI>Folic acid improves arterial endothelial function in adults with hyperhomocystinemia</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>7</NO>
<PG>2002-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yla_x002d_Herttuala-2000" MODIFIED="2013-05-13 11:05:49 +0100" MODIFIED_BY="[Empty name]" NAME="Yla-Herttuala 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yla-Herttuala S, Martin JF</AU>
<TI>Cardiovascular gene therapy</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9199</NO>
<PG>213-22</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-05-13 11:07:32 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hansrani-2002" MODIFIED="2013-05-13 11:07:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hansrani 2002" TYPE="COCHRANE_REVIEW">
<AU>Hansrani M, Stansby GP</AU>
<TI>Homocysteine lowering interventions for peripheral arterial disease and bypass grafts</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-01-28 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-28 14:19:11 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003285"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-02-07 13:33:02 +0000" MODIFIED_BY="Karen Welch"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-07-15 09:45:33 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-07-15 09:44:20 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-14 06:37:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khandanpour-2009">
<CHAR_METHODS MODIFIED="2013-07-14 06:36:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial - double-blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-14 06:37:00 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 143 participants agreed to attend the randomisation visit between February and December 2007 at two hospitals in the UK. A total of 133 participants completed the trial, seven participants withdrew consent and three participants needed surgical bypass for deteriorating ischaemia. All participants were white Europeans, 90 men and 43 females, mean age 70 years old.</P>
<P>Treatments: 46 participants received folic acid, 51 received 5-MTHF and 46 placebo.</P>
<P>Inclusion criteria:</P>
<P>participants were included if they had a history of intermittent claudication with a resting ankle brachial index (ABI) of less than 0.9, were aged 45 &#8211; 85 years, had a body mass index between 18.5 and 40 kg/m<SUP>2</SUP>, had been taking antiplatelet or anticoagulation therapy (aspirin, clopidogrel, dipyridamole, warfarin) and had received lipid-lowering medication (any statin, ezetimibe or fenofibrate) for at least 12 weeks before participation in the trial.</P>
<P>Exclusion criteria were:</P>
<P>critical ischaemia with rest pain or gangrene, awaiting vascular intervention, autoimmune vasculitis (such as rheumatoid or systemic lupus), diabetes mellitus (fasting blood glucose over 7 mmol/l and/or taking any diabetic medication), chronic renal failure (serum creatinine above 130 mmol/l), vitamin B supplementation within 4 months, methotrexate treatment, or other serious debilitating disease such that the patient may not complete the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-14 06:37:22 +0100" MODIFIED_BY="[Empty name]">
<P>Participants with PAD were randomly assigned to receive 400 &#956;g/day folic acid, 400 &#956;g/day 5-MTHF or placebo for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-13 12:46:32 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcomes of this study were the effects of supplemental folic acid and 5-MTHF on plasma tHcy, plasma and red cell folate (RCF), ABI and pulse wave velocity (PWV), a measure of arterial compliance. Secondary outcomes were changes in cardiovascular surrogate biomarkers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 11:52:41 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma total homocysteine values at baseline (n = 133): median value 13.31 µmol/l (interquartile range: 10.83-15.55 µmol/l).</P>
<P>Authors (N Khandapour and FJ Meyer) were contacted between 28 January and 28 February 2013 in order to obtain the results in the format required for this Cochrane review, but no additional data was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-14 06:38:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sydow-2003">
<CHAR_METHODS MODIFIED="2013-05-13 12:46:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 13:30:31 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-seven participants (22 men, 5 females; mean age 67 years old) with peripheral arterial occlusive disease and stable intermittent claudication who had elevated homocyst(e)ine plasma concentration gave their written informed consent to participate in the study. One patient in each group withdrew consent to participate after the baseline visit.</P>
<P>Treatments: 9 participants received a mixture of B vitamins, 9 received L-arginine and 9 the placebo.</P>
<P>All participants were on stable medication and doses remained unchanged throughout the study.</P>
<P>No exclusion criteria were specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-14 06:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomised to receive either a mixture of B vitamins (folic acid (10 mg/day), vitamin B6 (pyridoxal 59-phosphate, 20 mg/day), and vitamin B12 (cyanocobalamin, 200 mg/day); n = 9), L-arginine (24 g/day; n = 9), or placebo (n = 9), in three daily doses, for 8 weeks in a double-blind fashion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-19 08:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma homocysteine, flow dependent vasodilation, ABPI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-13 12:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>For the purpose of this review the data from the vitamin B and placebo groups were used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABI: ankle brachial index<BR/>PAD: peripheral arterial disease<BR/>tHCy: total homocysteine levels<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-07-15 09:45:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-07-14 06:39:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carrero-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-14 06:39:12 +0100" MODIFIED_BY="[Empty name]">
<P>Dietary intervention of fortified dairy products combined with increase consumption of fruit, legumes and vegetables</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-14 06:39:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Constans-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-14 06:39:24 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study of 18 patients with cardiovascular disease and hyperhomocysteinaemia (9 with PAD), treated with folic acid 5 mg/day + vitamin B6 250 mg/day for three months. Outcomes were changes in tHCy, vWF and soluble thrombomodulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-14 06:39:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Jong-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-14 06:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised study of 70 patients with hyperhomocysteinaemia treated with folic acid 5mg/day + vitamin B6 250mg/day. Outcomes were changes in tHCy and new cardiovascular events</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-14 06:39:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garg-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-14 06:39:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised study of 52 patients with peripheral arterial disease treated with niacin to lower cholesterol. Plasma homocysteine levels were also measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-07 09:37:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lonn-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-07 09:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with PAD were not reported separately and the trial team could not provide the requested information on these patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-07 09:37:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-07 09:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with PAD were not reported separately and the trial team could not provide the requested information on these patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PAD: peripheral arterial disease<BR/>tHCy: total homocysteine levels<BR/>vWF: von Willebrand factor</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-07-14 06:41:55 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-04-08 11:26:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-07-14 06:38:58 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-29 11:26:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-05 13:47:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>Randomly generated list by computer software</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 11:26:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-07-01 13:30:29 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 13:30:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>Randomisation organised independently; pharmacist had no contact with participants or trial coordinators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 11:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-07-14 06:38:58 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-03-05 13:48:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-14 06:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>Both randomisation and labelling of the medication was performed at the local pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-04-29 11:26:47 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-16 15:02:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-29 11:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>Randomisation code concealed from the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-29 11:26:45 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-05 13:49:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>All data accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-29 11:26:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>All data accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-29 11:26:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-05 13:49:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>All results reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 11:26:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>All results reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-07-14 06:38:13 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-14 06:38:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khandanpour-2009">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 11:26:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sydow-2003">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-16 12:41:42 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2013-07-15 09:47:35 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-15 09:47:35 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkcAAALtCAYAAAAixMB/AABqbUlEQVR42uydf2RX7///3+QlSRLJ
y2QSM+mTmZFJkolJ8vKWkUny+SMmySTxMjMziclkkhczSeYlkpdJJmaSSSIzk5fEJEkSM5kk19f9
+rie3+t5ds65zjnP53M/bzeO7fk851y/ntd5PO7n+vkf4/Gf//yHg4Mjx7HW4Deh/gFAFWypb1QB
IL8YIS3Abw6wAcURDxjA+nZQPMPUPwCo6nPFgwWwnh0UzzBQBwAQRwA4JxwjUAcAEEcAOCccI1AH
ABBHADgnHCNQBwAQRwA4JxwjUAcAEEcAOCccI1AHABBHm4nZ2VkKAeeEYwTqAMB6FkfRlVh/++03
s2PHDtPV1WUWFxc3hGEI3VdNg7N169bEsJ88eWLLt7m5uSrxpt0fjQs2rjj6/v27fV63b99u619H
R4f59u1b2TVjY2Nm37599vzhw4fNzMwMZU/9A+CZShNHUSSKrl27Zi5durQpDEM1w00LS2Ll6dOn
6zIuWLvi6MqVK+bOnTvm169f9rh+/boVSI5Xr16Z1tZWMz8/b88/ePDAHDhwgLKn/gHwTOURR0JG
VG+iPv39/Wbnzp32++7u7rJzP378MOfPnzfbtm0zjY2NZnp6uuy8DLbu0/njx4+bjx8/lqXh5cuX
Zs+ePaalpaUUv8SZWrHq6ursm29cK8yWLVvMoUOHzNTUVCaDEgo3lE9dOzo6aurr623cvgiJ2w/J
/5t0Lku8WdLtpzEurmgZZ/ldRkZGzO7du82uXbvM33//bW7dumXTEBVfm8Vor0VxpN9G9cPx8+fP
shbMzs5OMzg4mCueuLqyXp9/6h8AVE0cCV8c3b1714oCGS0ZXxmrmzdvls739vaahw8f2v/Hx8fL
3kzlUIeHh0tvtgpLhtRPw+XLl+25T58+2e+GhobMjRs37HdfvnwxR48eLUur75wnJibM/v37MxmU
ULihfOra06dPl4y70qC0JJWn/zntXCjeULpDv2tcGWf5XS5cuGDT888//1hHdfHiRfs5mm/e3NdO
3BIqEhoOCfk8Y+Hi6sp6fv6pfwBQFXH04cMHa5xksBwau+K/nQrfIMkYRs87Dh48aA22b7zVGuGn
wX+TFHqD9O95/fp1WVpl/J0xzmNQQuGG8hmX1qwCKO1cKN5QurOIo2i68/4u+rywsLCpDfV6EEf3
79+3YsUXEhIQatFRy03cmKRQXVnPzz/1DwAKiaPooWZsNYPrDdE3sNHr1KTtn0/Cvy7u+ri0RcOT
4fWvk7HXZxntvr6+zAYlFG4on3FprYY4ylu+0XRnEUeV/i5ZwsQ5rW7cX79+NWfPni17dnWfBmxL
2LqWG3W15YlnPT//1D8AqKjl6PPnz+bkyZOxM1niDFyaMQudSxMNWe4RGqegJvz29nY7gLyIOIqe
D+WzVuKoSPlWKo7y/i6Io7UtjiSIzp07Z7uhfNQd6rfCSGhEZ1UWEdLr5fmn/gFAReLIGViNqdEY
Ex8NevS7VKI0NDQkNqvr3mizum+c49Km2TX+PXNzc4mGQWIuq1AIhRvKZ63EUSjePOWRVcjk/V0Q
R2tXHKnFSK1DmpEWRS880VYYda/liWc9P//UPwCoWBy5FiSNJ/ANrQZVugGSOvRZs04cGuOgpm4x
OTm5bEDm7du3S/dq2rGMaVoaNN14YGCgNCCzra2t7DqFrxkrIjQ42L8vFG4onyFxJKej8RPOsGcV
R6F4Q+kuIo7y/i6Io7Upjl68eGGOHTtmn9s4NDZHh/ud9ZtrraM88azn55/6BwBVEUfOwMng+vT0
9Ngmer31qXXJzSwRS0tLdqCnjJQGYGoApY+byqtDM1XevXsXTIOmH2vgpqYPa5yEf52a1BWPm07v
DGWWPKaFG8pnSBxpBo/uc2/Gebqp0uLNku4iQibP75KnVQzntHJx7927N3bsoI/EiQYxu7r177//
5o5nvT7/1D8AyC2OAGB9iyOg/gEA4ggAcQTUPwBAHAEgjniGqX/UAQDEEQDOCccI1AEAxBEAzgnH
CNQBAMQRAM4JxwjUAQDEEQDOCccI1AEAxBEAzgnHCNQBAMQRAM5pIzjG2dlZKsEqlgN2HABxBIA4
yhB3KE3VTHN0w1o/bK1SrdWqm5ubqxJv2v3RuFaatHJAHAEgjgAQR2s87mqmOS0siRXtc7Ye46o0
bYgjAMQRAOJoDcXtf6+NWi9dumT3QKurqzNjY2PL7uvv77f7lWmfs+7u7mVhjY6Omvr6+tK+ZU6E
xO3d5v9NOpcl3izp9tMYF5f2W9P+cS0tLaVr3Z5u2hBaG+VqU2g/nJGREbt/265du8zff/9tN8lV
GtLEV1L82r8urtyy5B9xBIA4AkAc1UgcDQ0NmRs3bpR2sz969GjZeW3gKvGj8z9//rQiRJsl+2Fp
U1knIqI73ufZfDhPvKF0Z2m5uXz5sr3fbYgroTM8PGy/06E0aNNb/54LFy7Y9Pzzzz9WFF28eNF+
juY7S/ynTp1KLLdQ/hFHAIgjAMRRjcSRWk1+/PhR+vz69euy8xqjIwfts3///rKw/NaVPAIo7Vwo
3lC6s4iTaLoPHjxYFqb+VytR0j36vLCwkOm3zhJ/nvwjjgAQRwCIoxqJo2hrhxxy9Hy0W0jdQGlx
VEMcheINpTuLOInihx8XTyiMSuPPk3/EEQDiCABxtELiKHo+5JBrJY5C8YbSXUSchMJcSXFURAgh
jgAQRwCIoyqIo9bW1rKupLm5ubLzhw4dKus6WilxFIo3lO4i4kRxRrvV/Cn4KymOQvlHHAEgjgAQ
RzUSRw8ePDADAwOlgc1tbW1l5zVI2Q181qHPmsWV1clr1pfG1jjRkVUcheINpbuIOFEcmkHm4rxz
545paGioijhKK4ci+UccASCOABBHNRJHYnBw0A481rRxzZKKnu/p6bEzs9SKoplpbnZXFievGVa6
z7XA5OmmSos3S7qLCBk3lV+HZqq9e/euKuIorRyK5h9xBLDGxNHXr1/tuhtaI0T99Jrloamm0Ycy
6fCvid4XZ0CzhOMfSpOMSldXl1lcXFwW/uTkpL3u2bNnFRuT79+/23hkTGXEOjo6zLdv3zKf1/8y
fHqz1DVnz561b8KAOFrPcQP1D2BTiSOJDU2j1Rocron41atXZt++febevXu5Hkpdo7CWlpYKvfGm
fa90Xrt2zS4UF+W///2vPffHH39UbEyuXLlim99d87fePCWAsp7XQm99fX2l8/fv37dvjIBzwjEC
dQBgnYij3t5e2/8dRQLJX2k2qzj666+/rDiotjgSEhtqjfFR0/TevXvt/xJ0nz9/rsiYaKVcfz0S
LdjmD+IMnT9x4oQdTOqfP3nyJDUQ54RjBOoAwHoRRwcOHDAfPnyoykPprjl8+PCyxdWqIY5EVBxp
EOeff/5p/1cLjVpuqmlM1Jqm7sas59X9F13sTd8BzgnHCNQBgHUijtKWyI8+lFnGConnz5/bsTbV
FEcScNpiQFsE+Ggvo/fv39v/5+fnbetRNY2JusXUupb1fFx5Zi1jwDnhGIE6ALAGxJEGDlfrofSv
kTiSSCoqjqKHNqPU+B51UzkmJiaWTYfVFGB/YHYlxkQD1ZUPP87Q+dCqvIBzwjECdQBgjYujpqam
2NlUcviPHz8uLI7U0qPutaLiyKExRBqzMzMzs+w6zQqLE1L6vlJjovyfO3cucaZZ0vm4LjS61XBO
OEagDgCsI3GkwdOaqRZF3UVHjhwpLI5c2BqgXWm3moSIBI92znZoTJO61KLje/RZ37uB2UWMiVqE
NF1f3XR5z7e3t9vp/g7N3Cuy2BvgnHCMQB0AWCVxpHV5tK6RpqfLqUtcPHr0yM7Kct1iRcWRhIF2
o67GmCOJHe1i7QSJhFfcLDuhxeTcwOy8xuTFixfm2LFjy2a9ZT2veP2VcEdGRpbN3gOcE44RqAMA
a1gcCXWBqYtIM8E0ZkZT+LWwYvShzDog20eLQlZrtprSJGEi1B0YXU/JIZGnvYyypttHywKkXRs6
r6UFNO7JrZ576tSpskUiAedU7bi1BpjW39Lq0hrfppeI6KzNtVImIXuBiEAcAawZcQQA61ccdXZ2
2m5w18Ws5SU0eUHHZi0/xBEAII4ANrE4ipsNqdYkdY3792rFe7UuqYVYS2JEW17V2qR9zXRe2wn5
SHBpbzLNbm1sbDTT09Ox6dKyGm77HKVL1yZN7PD/f/Lkib1eLddq9Z2amsqcNolCrZyviQ+a1ZrW
Wk39AwDEEcAmEEdayFUbobrtf5Lu1fg/TWSQmJDYUFecQxu9amKGzmkChASGwnRoLa+HDx/a/8fH
x22ccelSd/eDBw9KY+6Gh4fLFklNEkcSRk+fPrX/a4kOdQ1mTZvWP3Pj/DR79OjRo4gjAEAcAWxm
cfT69WsrJiQwNMZNM0T9yRTuXr+1R+Py3LY7QsIpOvPTFygSQ9HzWcvEX/srSRxJQDnxFSWUNo2R
9IWhygNxBACII4BNLI4cL1++tK0o6taSUNKsTf/eqMDwu+P0f3SSgS9q0hYyjaZL6VBLk8ZCaSZs
kiDy/1drkWvdis7uzJs25RNxBACIIwDEURmzs7NlrStx9/qiIm5l96Rr09KlcU1qZdISFlqpXrM3
s4gjJ6rUZae1wq5du1ZR2hBHAIA4AtjE4kgDr+O6vPxNmnWvv8q8lpfwV27XIOiFhYXEuBsaGjJ1
qylMPxytS5ZVHDmUTv9cKG2tra1l3Wpzc3OIIwBAHAFsZnGkKftaEFXrlQnNQrt9+3bZJs26Vyu1
a8CyRM6ff/5pzpw5Uzqv+/3FS/XZX9ld3WTq+hJabyxpQLZWp3ez0yRStIVQFnGk8DRjTWhgtt8a
FEqbBoAPDAyUBmRrnTHEEQAgjgA2sTgSmn2m1h11QWm6vgST35qieyVafv/9dzv4+erVq8sWJ+3p
6bEtP1q8VOOW1CXmkODq6OiwokXjiDToOS5dGgjuBodL8GiQdRZxpC41hav0614nlLKkTWh8lfKt
6f6a3YY4AgDEEcAmF0c4VeofACCOABBHOFXqHwAgjgAQR8VQdxRQ/wAAcQSAOALqHwAgjgAQR0D9
AwDEEQDiCKh/AIA4AkAcAfUPABBHAIgjoP4BAOIIAOe0fhyj9nUDxBEA4miDgXGnjNaTOIruWK8V
prWadFdXl1lcXFzxvLNsAOIIYF2LIy3X//Hjx7LvtMWArtXu2D66TtfX6qFOO5/mFGphdKLGvUg8
ckrawkHbNchZ7d27135O20BzPRnYapQRzql64iiu/mln+0uXLuHAqX8AkEccab+iv/76q+w7bVZ5
9OhRc+XKlbLvdZ02q9wM4igabt54tKeVylCbZX79+tV+p00xtX/UiRMn1oRAwkhvbHHk6tz27dvL
vtMebNp/TN93d3cvu0fn1eq0a9cuMzw8nPhcaO8ziX7thXbo0CEzNTVVusY/ssSr6/RsaM+3lpYW
rDXPHcDqiqPp6Wnzxx9/lH2n1qEXL14sayXSdbreoVYQGbpt27bZHbL9Fqg4Y+fHL6OtN1oZ4bq6
OjM2NlYVcZRmgN+/f283rFR6ZdQbGxtLu4f7YcUZd/3VLufacdxtjKmdw5OQKNLO4XHcu3fP7nAe
cgxpTipLXkZHRxPTm5RXHa4+pMWRVEY+ofqRlj6cU/VeEnxxpA1ZVe56/n7+/Gmfu5s3b5bO65xa
m9zu9keOHEkUR/5vNjExYTebTUpPKF5dr5cynY9uKAuII4AVF0dC4kRGSXz+/NnupC3kDJ2hkkFT
95BDjl8OW/fpkPE7f/58qrHz4x8aGrICwhlhtbJUKo5CBripqck8ePCglGalX4Ika8vRqVOnSg5e
TkHOIQnFldQ6pPz6wjOurEJOKkteJGyS0htXnt+/f7e/ubsnT3lFP2epH2npwzlVLo4+fPhgnzPV
LUdzc3PpWXf4oqa1tdXaAMfr168TnwvVhYcPH2ZKTyheXR/t3gfEEcCqiqP//d//tU3kQoLCdafp
r5yj0PijCxculLUuqevIof93796dauz8+NVC4t8fNcJxBiHpyGqA41CrRVZxlJafKKEBqf75uLBD
TipLXtLSGxeWxJgvJvOUV/RzpfUD55RfHEUPvfSo9U4vCn5rT/Q6/zeN1ls9T0n1Rq1F+qznrq+v
LzWdoXhx+IgjgDUnjtRV4t4uz549a42eM376LNQF5nfb+IbNN4BpD3C0ST7NCBd5Yw4ZYKHuK3Vp
dXZ2WgeeZPizjDmqpjgK3R9XPlnzkiV/c3Nz1slFyROH/7nS+oFzKv4cSFSfPHnSzMzMpIrbOELP
ZVwd1ItTe3u7FddJ14XixeEjjgDWnDjSm2VDQ4P93+9i01+N33Hn/ZaAuC6QPM45dH8RpxAywBrr
oy7DkZER8+zZM9uFVStxJKGRNIVa3VcawJoWTshJ5clLlvyp2+7Vq1eFyyvv74s4qp04cs+0ui3/
+eefsu9V79ImAxw+fNh24zrevHkT/N2EhFjadaF4cfiII4A1J46EDOm5c+fMf//737LvNThX32m8
TdTYRbtNQq0h/nfqNvLvV8tFpeIoZIA1uNk/Pz8/XzNxpDE3GsAdh1rgNEswLZyQk8qTl1D+JH78
cSlF44j+FpXUD5xTZeLItSCpW1m/m18v3Vg/HfqswfKO6Fg3nUv6zSWcXXd8dMyYBuGr29TVgVC8
OHzEEcCaFEeapq/zGjib5Xvn/J2xu3PnTqn1KYvz01imgYGBkhFua2urWByFDLBmRrmuQYkxCZAk
wx817nmdud7clSeVkRMYStPk5KTt8vj27VtqOCEnlScvaeJIywxoXEocoTjSyqjS+oFzqlwcCdW3
Y8eOlX0nYS7hK7Gql6Lo7DA9l2oxViuynvskUasuNXW1utmGTigJjV3Tff69afHi8BFHAGtSHLku
E81w8dHnpJkkbqq2Ds1EevfuXS7nNzg4aAfpyhDLCFdjKn+aAX7+/Ll9k5Yh11uvZtokCYqocS/i
zJeWlmx6JDLcIpASPL4wSgsnzUnlyUuaOFJrYdIg91AcoTKqtH7gnFY/btVh1Vug/gFsSnEEaxuc
FM5pJeLWy4oGWLvlMCRw/YHWgDgCQBzBqoGTwjmtRtwaeK9lNtQaqMVHr169WrYUACCOABBHsGrg
pHBOOEagDgAgjgBwTjhGoA4AII4AcE44RqAOACCOAHBOOEagDgAgjgBwTjhGoA4AII4AcE44RqAO
ACCOYG0zOztLISCOgPoHACFxpG0kuru7zZ49e+yKyNoWYGxsLPGhzPOAVuthDq2gnXRUK21F8xFN
j8pXq3h3dXUlbk5bS6Ppr7RdrXijh78JcOg8zgnHCNQBgDUnjuSgtaaO9vNy+2Rph/Z9+/bZndnX
ykOZNf5apbMScRRX5lrU8dKlSxvOuGoneH9j3bzncU44RqAOAKy6OOrt7bUbhUaRQJJoinsoo/9L
WGkPMbcJpXbpjrtW4kv7bGnT0sbGRjM9PV069/79e7sfms4pDJ13G59WQxzpe22WqdYxly//2jzx
a5NNXaP8agf6qamp3OnR6tfad8ynv7/f7qem79WSF0Xn1eqkhSGHh4cTf5Ok9MW1qvnl8j//8z+m
qalpWbxagFLbl4RaupQn3Z90Xeg8zgnHCNQBgDUhjrSpaHTD2dBDGf1fosJtTithJMccd62EmDYw
FdoeQ3E75DQfPHhQ2sldzl8Ou5ri6PLlyzZstyGtf22e+H0BODExYTdoLWLMfHGkzWUlMt2WIerW
1OauDp1Ta5POf/nyxRw5ciTxN0lLXzQ90XJpa2tbJvYU98WLF4NlrzyktQqFzuOccIxAHQBYE+LI
FzJFxZETRqFrJYbkhLMSHbtSqThKS2ee+CWanMgrkh6J0aGhIStKHM3NzcvKxhc1ra2t5vPnz6XP
r1+/TizntPTFiSO/XCRa29vby65RS9ubN2+CeZXAnJ+fL3we54RjBOoAwJoQR+pGqlQcZb02JMTU
vaPWpc7OTjsovMgg8DRxFPoua/xqjdFnCZq+vr5geqJHXV2d3UzW3y9NZZM2cDk6kFpCqkj64sRR
FHWRvn37tiTC/O7VJHT94cOHC5/HOeEYgToAsGbEkd7m1U0TRY47acxNLcSRBn+rZWlkZMRuvKou
npUUR3njl5ByrSzq7sqSHrX8nDx50szMzCy7LjSDK1p2aeIoLX1ZxNHAwICdTSc0Ruyvv/4Klvvt
27et4Ct6HueEcwR+e4A1I47UsqAxJVHu379vx7VUUxw1NDQkdqtpoPHCwkLps7pfVlIcFY1fQie0
zEBUdGqMlmZt+WjgtB9/FLW6+CJW3VxF0pdFHCketShKzGmA+NLSUrDcz5w5Y8VY0fM4KJwk8JsD
rBlx9O3bN9uFdOfOHfP9+3crXh49emRnRD1//ryq4khdVuryEZOTk2UDstWV41qq5ubmrBhYSXGU
J36lWzPCRHQAepZ4JTo0nsgff6MZgzdu3CgNCNfn48ePl85HB2TrXJH0SfRojJFbtiGpvNRi9Mcf
f5SNi0pD+XED3Yucx0nlTwfH5jkAYIXFkdAA4XPnztnZU+re0RgTiZcsgiePOFILREdHR2mhSY1n
cUiIyYHqnJy7BhSvpDjKE7+6rJR+t3SBEyJ50qPyPXbsWNl3msmlFiyNL1LrUlRMqLtLLTkas6SZ
X/44pKzp0ww43efuTUqfllnQuawraiuetMH2ofOII6D8AWBNiSNYf0hoau2hWiFhptY0wDlT/gCA
OII1ye7du+2YHbcOkgY3pw0ErwTFoVas0Ew8nDNQ/gCAOIJVQzPo1N2p7jCNB7t69WrZUgDVROOS
Tpw4kWkgNs4ZKH8AQBwB4JyB8gcAxBEA4JwpfwBAHAEAzpnyBwDEEQDgnCl/AEAcAQDOmfIHAMQR
rBZZF1YEnDNQ/gCAOKrYCGo1aK3GrB3pq5mW6BHdKFbrDml1a02D1yrg2iIkCX9l62rkH4eBc6b8
AQAQR4lIGGk/sVqiTWO1SKJjcHDQDA8Pl/ZF0zYf/r5otTbwOAycM+UPAFBFcaTvtRfXnj177CKD
jv7+fruPl/Zb6+7uLrtHm5ZqY1K1kjQ2Ntp9uHzUiqL7dF4iQRudpsUnQXHp0iXb8qJ9w8bGxsqM
oGsNUmuNdq+fmppKzEvcZo1505OG0trU1GQWFxdL32lPNm3aGxVpWdMYlwY//e/fv7d7rSn9Cldl
7jbJjV6btawA50z5AwA2JUUcaed1OX230ak2NdUu8G6rCokVbVjq6O3ttRuzCm1poY1aHdpN3m9F
UVgSUmnxDQ0NlXak147zR48eLTOCfmvQxMSEFSNZjWeR9KSh+/1WoygLCwtWWHZ2dmZOY1wa/Gsk
xh48eFDKg/IjIRUXXp6yApwz5Q8AiKMEY+O3pAiN14nuoO47WYmhpB3WtRu8Wpb8VibtC5YWn1pL
/Htev35dZgQlBJwYy2s8i6QnDQmV+fn52HNnz561LVQ63rx5k0scRdMQcgL+mKeiZQU4Z8ofABBH
GY2NWh/SBiAndRlFnXbc9Unx+Uh4+depBUSfJdpCm6FGwy+SniTevn1rDh8+HLxO3Xjq0sojjkLX
qNtNLXZqkZLg888XLSvAOVP+AIA4ymhs4gRFmpgJnUty5FnvceJAXXjt7e2pu9FH7yuSniRu375t
hU8IdUWmlVFecXTv3j3bWjcyMmI3oFXXW1oespYV4JwpfwBAHGU0Nmr10NiZJBoaGhK71XRvtBvL
n7oeF19ra2vZPXNzc4lGcGZmJtVARs8VSU8SZ86csaIjirqyNFbKj8PvuqtUHGmguv97qFsvi8AL
lRXgnCl/AEAcZTQ2GsTsBkjr0Gd/arq6d9R9IyYnJ5cNyFYLi7v3zp07VkylxafBxpr+7gZkt7W1
lV2n8DULS2iwcZ5WmSLpSULjruIGbas1SV1YLo4///zTHklo1pnGGDnRFhJH9fX1pdlpEo7q2ksS
R3nKCnDOlD8AII5yGBvNyFKLhVpZNI3cFwVLS0t2oUM5Xo1/0QDqqFhwA5M1M+zdu3fB+LRWkFpb
tHyAZoT516mbSPGou09xOuefNT9F0hOH4o5rMVM3mmabqawUR6jrTTP/dK1rwQqJo+fPn1thpvgl
fjTgOkkc5SkrwDlT/gCAOAIAnDPlDwCAOALAOVP+AACIIwCcM+UPAIA4AsA5U/4AAIgjAJwz5Q8A
gDgCwDlT/gAAiCMAnDPlDwCAOALAOQPlDwCIIwCcM1D+AIA4AsA5A+UPAIgjAJwzUP4AgDgCwDkD
5Q8AiCMAnDNQ/gCAOALAOQPlDwCIIwCcM1D+AIA4AsA5A+UPAIgjAJwzUP4AgDgCwDkD5Q8AiCOA
FGZnZ3HOQPkDwMYRR1+/fjXd3d1mz5495rfffjMHDx40Y2NjiUYpj4GqljGLxp90VCst68kILy0t
mYaGhtg8RI8tW7ZkPp+HrVu3Vv03xjkD5Q8AqyKOFhcXTUtLixkdHTU/fvyw37169crs27fP3Lt3
b80YpaT4a5Wu9WKEf/78ac6cOZMpvf/884/p6ekpfL7W5bUeyhznTPkDwCYQR729vebWrVvLvpdA
kmgKvdXrfwmr+vp62+qglqenT5/GXivxdf78ebNt2zbT2NhopqenS+fev39vTp8+bc8pDJ1//Phx
YXGk71++fGlbw1w+/GvzxPfkyRN7jfJ36NAhMzU1lVrY/f39ZseOHWbXrl1meHh4WRqvX79utm/f
buM+fvy4+fjxoxWpe/futa1APiozxZmE7v/w4UPQafz69cs0NTXZeIqcTyuHuNa7uPT43ym+S5cu
2XKqq6uzLZVpLUcq0507d9pyUytnlnThnBFHAACFxNGBAwesc81jlKL/S2TIwQsJIzmquGslxB4+
fGj/Hx8ft3E75JgfPHhgnaYOiQoJm0rE0eXLl21Ynz59WnZtnvh8wTcxMWH279+fWE4SiteuXbNh
fvnyxRw5cqQsLAlRxeXivXv3rhWMoqura5lQHRoassIgiWfPnmVyGoonrVUodD5UDtH4Q+JI+bpx
40apnI4ePZpYx5Q2lauuVUuZhNTNmzcL/T44Z8QRAEBQHPlCpqg4csIodK3EkBxcVqLjY/KKo7R0
5YlPosmJuhCtra3m8+fPpc+vX78uC0vjuVz3pWsZ2r17t/3/7du3tvXIlZH+qnszmo8iTkNicH5+
vvD5UDnkFUdqzfPLIVpO/v/Nzc3L6o0vgPL8PjhnxBEAQFAcqWunUnGU9dqQEFM3mFqXOjs7rYjI
MkA3z/fR77LGp9YIfZaT7uvrS81DdGCynLofVtyAZ79cjh07ZltJhFq21CpXqdOQ6Dp8+HDh81nK
Ia84itaFaDlFr00bOJ7n98E5I44AAILiSC0G6taIou6LpDE4tRBHGvytlqWRkRHbVaSusFqKo7zx
SUipK7C9vd12myURcvpxZeCfVxwa/yQ0fsZ1m1XiNG7fvm3HORU9n6UcKhVHafUmywy6rL8Pzhlx
BAAQFEd603YtFT7379+342WqKY403TypW00DcxcWFkqf1cVTS3FUNL6ZmZlUA60WGF9svnnzpux6
CZ5ot1q0tUmD2zUmR11q1XAams0m4VD0fJZyCImjaPmq+9Evh7m5ucTwVGb+b5UnXThnxBEAQG5x
9O3bN9uldOfOHfP9+3crXh49emRnWj1//ryq4khdWOoCEZOTk2UDsiUIXEuVHKVERi3FUZ74lE7N
iBLRAedRogOyNZssOiBbLTVuQLbKPbpGkQYbawaXP+i4Eqeh8TluUHqR81nKQd2zGhvlBI8/SFoD
/tU96KdRXYYDAwOlcmpra0ssf5WZG7ytQ59VrkV+H5wz4ggAICiOnPM6d+6cnSatLgwNlpV4ySJ4
8ogjTVPv6OgoLTSpQbgOCTE5aZ2Ts9MA21qKozzxqctG6XVLFThHnBSXnL6mnUvgaKZVtGXITeXX
oZlq7969KzuvRTl1T1x3ZxGnoTSnDYQPnc9SDhJySrPLqxMpulbiT9dG0zg4OGgHo6usVE5pv7dm
0qm1T+FLaPliLvT74JwRRwAAucUR1A4JQs1AA5wzUP4AgDjalKglRON33Jo8aiWq5QBhwDlT/gAA
iKM1jWaXqVtS3T8at3X16lUrkgDnDJQ/ACCOAHDOQPkDAOIIAOcMlD8AII4AcM5A+QMA4ggA5wyU
PwAgjgBwzkD5AwDiCABwzpQ/ACCOAADnTPkDAOIIAHDOlD8AII4AAOdM+QMA4ggAcM6UPwAgjgAA
50z5AwAgjgBwzpQ/AADiCADnTPkDAKTZFAwLAI6Z3wAAICKOMC4AOGV+BwCAiDhyBoaDgyP7AYgj
ANjg4ggw/AA8IwCAOAIMPwDPCAAA4gjDD8AzAgCAOMLwA/CMAAAgjjD8ADwjAACIIww/AM8IAADi
CMMPwDMCAIA4wvAD8IzwjAAA4gjDDwA8IwCAOMLwAwDPCAAgjgDDD8AzAgCII8DwA/CMAADiCDD8
ADwjAIA4Agw/AM8IACCOAMMPwDMCAIgjwPAD8IwAAOIIMPwAPCMAgDgCDD8AzwgAII4Aww/AMwIA
iCPA8APwjAAA4ghWw/BzcHCkHwAAiCMAWikAAABxBIA4AgAAxBEA4ggAABBHAIgjAABAHAEgjgAA
AHEEgDgCAADEEQDiCAAAEEcAiCMAAEAcASCOAAAAcQSAOAIAAMQRAOIIAAAQRwCbSRSxnxcAAOII
ABBHAACIIwAICyQAAEAcAfDAII4AABBHAIA4AgBAHAEA4ggAAHEEAFkFEgAAII4AAHEEAIA4gtV3
whwcHNkOwG5wcFTLbmBRaJ0A4JmhDAB4ZhBHGDgAnh3yDgDxzw5PEwYOgGeIPANgNxBHGDkAniHy
DACII4wcAM8QeQYAxBFGDoBniDwDAOIIIwfAM0SeAQBxhJEDAMQRACCOMHJQE2ZnZymEdVoOiCPq
G3kDxNEmNHIPHz5cdt23b9/M6dOnzbZt28z27dvN2bNnzZcvX0rnv3//brq6uuy5rVu3mo6ODnsP
TuD/ePLkifntt99Mc3Oz/awyWm/58cOqVrgrVQ4Ihdrl+fr162bHjh3WNui5//z5c9l90WPLli1l
94+NjZl9+/bZunD48GEzMzNTs3zUor6tlfoQylvUBq1GHQqtIr24uGiuXLlidu/ebdO6f/9+09/f
vyysr1+/mu7ubrNnzx573cGDB209QhxBzR7kDx8+mOPHjy+7ThW0r6/P/Pr1yx737983PT09pfOq
0Hfu3Cmdl8GUocTx/R96gJ8+fbriBrVW4mgzCw3E0f9ncHDQDA8Pl577gYEBaz+S+Oeff8rsxqtX
r0xra6uZn5+39z948MAcOHBgXf12a6U+hNIRtUFrMa2dnZ3Wt6guiB8/flhfosMXUC0tLWZ0dNSe
d/VIAvvevXuII6jNA9Te3m7+/fffZdedOHHCzM3NlT7//PnTnDx5svR5165dpQrtzqe9ySj8ly9f
WuWviu6LsJ07d9oWKL0Z+OhBOH/+vH1DbWxsNNPT08veYHWfzstAf/z4MTU+pffSpUv2rbeurs6+
efj5dm9aetM9dOiQmZqaSszP+/fvSy1rukfpe/z4cfCNyY8vLe9J5eUTyk/sKq2R8zIuemtTGi5f
vmyWlpaCLUdpv0uecslSDnl+E8RR7fOsN3u1GkedcFL9bGpqss7Nd4YSWHnSIadYX19v60Ccw0+y
A1n2vCpil+JeJKPXKs979+4te57cs6N6HHpWQnkP5S3ufFJeQ3Z0ZGTE2gjZ/L///tvcunXL2pw8
4iup/OPqjspOcTl6e3ttnFEkkJJsI+IIKjLseuvTW2Dcdar8vvhx3yWhh14PXVo65HwV5qdPn+x3
d+/etQ+/vpO4knO/efNm2UOhLj8xPj5e9oaph8V/g1VYcthp8Q0NDZkbN27Y79RFePTo0bJ8+w/7
xMSEdQRJyOjrrdfFr7T4+V/2YEQ+h/Iel/4oofxkEUdqcpcxVBgy8moRDImjtN8lb7mEyiHPb4I4
Wtk8Lyws2DojwROHflu/1UjI0ecZK6N0SEA4h6264DvULHYgFH5eu+SHmXathh1EnbqeWddtlOVZ
Sct7lryF8pql/C5cuGDzplZA+YCLFy/az9H0FKlPsh0qL9cilHSNejjW+zOEOFonRk6qW61DSdfF
Vfq0B0FNo3Kaaenw30iEHHNUgPnOTw9F9LxDfc7+A6X/9XaTFp/eMvx7Xr9+XZZvGSbn9Ivgj60I
iaNQ3uPSHyWUnyziyG/1UYuA3nZD4ijtd8lbLqFyqPQ3QRzVJs8ag6jWBh1v3rxJfIFQ91nUhkjk
qpXEjVlKG6sY9xz4actiB0L5zGuX/DDTrn379q19ntx5/VVXUNpzHX1W0vJeRBxFw8trR/VZojjv
s5F0nWyWykv14tSpU+avv/4yz58/z+x3EEdQVSPn+nCjAymTHtJQJdVgORlLvU3kSYfCSxu8mfZQ
hNKXFJ+PjJV/nYy2a03ReKsQaqKWINSbs4xMmuGKE59pec9idEL5ySKOooY9qQyjLWzVKpdQOeT9
TRBHK5tndcm4biIfCQMNto4LVy0qcrCupSKp5SlLHS5iByq1S9FnIe3aY8eO2ZYloVYitQQVfVaq
IY4qtaNZwixSn1QOalVT+Sh+v+tVIhpxBCti5NRM+ujRo9Tr4rrQ4r6TIDp37lzZTLas6Yh7MLO+
McSdCxmO0D3uIVVXkcZiXbt2LTF+jdVRC4r64589e2abqfOIo1Dei4ijLGWQp4yKiKO85RIqhzy/
CeJo5fOs5z+uPty+fbtsUK1vQ/yWCgmk0FjFtO+KPAOV2qWQOPNRvVUrmZCI1DNR9FmphTjKW361
Ekc+6nb1W+rUAhnnX1T3/DFaiCOo2MhlGSwsR+QPvNTAwuisFLUY6S0w2nSeNR0yFn4TbZSGhobE
7hvdG20O9o1sXHyaJePfowHnSQ+tphenPdAy8n7aVQZ5jEoo71mMSSg/0TDi0uhPo1b3hi+Ak8JK
+13ylkuoHPL8Joij2udZ3Zy+o4p2wzjOnDljhUEUf1KHE0dpLQMhgVDEDlRql6Lxh+qvxlmpVURd
apU8K7UQR3nLr9riKDqxx6HuWodajF3rm4+Gchw5cgRxBLU17HEzMNxgXx16u/G7NV68eGGbjP2u
ubzp0GBAPw599gWYmpvVrSImJyeXDcjW26m7V8sKyGmnxadmbQ1CdwOY29ralo2l0ewoERpsKIPn
3lokStSFkGa45ADUd+8MUSjvWX63UH78wcwa0Kgm62gaFafuVRh//vmndWohQ5z2u4TKJW855PlN
EEe1z7Nag/wlPlRndETRm3/cRAKNH9Ph7tczHNf9llUghOxAtL5Vwy5F40+7VmjAsWaT+oO6i9iQ
6Hd585aU1zx2tNriSPVJaXADrvUSrvRo4Lj/0qYuR6VNL+xKp3o+JKyi45MQR1BzcSTDJmertwgd
GiznD5zUQMO0lqes6dBsFr1BKQ45b9+g6kHRgE236JcG70UfLDcoVDMs3r17F4xPfdl609XUW413
8K9T943icdNmnVOOQw+lG0goBx5dSDMavwyjK8ssec/6u6Xlx4kJ5UcGT/mJplHG+ffff7ctAlev
Xi37jZPyk/a7hMolbznk+U0QR7XPs7oy5Lj0W+m5i+s6c8I8qXVRzk/1zf3eWkqkqDgK2YG4+lap
XYrek3atUAu7zkW7hvLakOh3efOWJlCy2tFadKvpRVz2Sc+4bJnSExV8Ek8avqE06jqNmdWL2Xp6
hhBH61QcAXUDKCfqBgDiCCMH1A2gnMgzAOIIIwfwf6zHfc54hsgzAOIIMHIAPEPkGQBxBBg5AJ4h
8gyAOAKMHADPEHkGQBwBRg6AZ4g8AyCOACMHwDO06nkqsi4ZACCOMOwAsKHFUdIirtiNdLT/V5Fz
lNH6CR9xhGEnnwAZ6lbanoQb8cAmJBNdBsOPK+3cZirDWi8VstaXIkEcIRrIJ1C31mGeaDmqTZ0o
usXGRqv7tc73Wi9XxNE6rdz6XvtWaY8j7VPj0D432qdLe9h0d3cvu0cb0Gr/G2369/fff9tNA7Wv
kL/JqcPt2aMNErUZozZJXFxctPuyaX8uH+2lox2is6RDezZdunTJxqsNHcfGxjDmgDgqII7y5ll7
27n9+vS8Tk1NlT3D2ptLz3tjY6OZnp6uyN5ksUfarV0buLq993wbFBV7ade6uGRTZNuGh4dTbWdU
UCa1LsaVZVqe0so3jjgbGypzn/fv39v94HS/4tXv5jbDdWEoTPe7njx5smwvxaT0JpVDND2h+JPq
VFz4ecsOcYRhT/xeG0hKaLiNErVxqQyIvtMGkxId/k7SuufChQv23D///GMNycWLF+3n6I7pEk0y
MG63Z4WtSi66urrseZ+hoSFrNLKkQ9e6nbC1mePRo0cRR4A4WoE8+6JiYmLCbpzq6O3ttZunivHx
cbuZaiX2Jos9kmN1giBqg6LiKO1axXPt2rWSTTly5Ejh1qG0c6E8pZVvlDQbm1TmUZqamsyDBw9K
YSg8iRc/jNbWVvP582d7/tGjR9YHZElvXDlE0xOKP1SnstZNxBHkEkf+W4Zobm5etpN2tLJH30wW
FhZi49JO6v7OyvpfLU7i7du3tvXIxaW/+/btK4UdSofeOvyw9SaDOALEUe3zLMflnFUUOa7oc1uJ
vclrj9JESuhaJwCy2pSi4iiUp7TyjZJmY5PynAW1vPhh+C1FSrvykCW9ceWQJT1+/KE6lbVuIo4g
lziKeyuMNldGH5SsBsK/zw/fcezYMfsGJfTmoLe6rOnww3EPLOIIEEe1z7PeyHVODrKvry/x+a6G
vclrj0LiKO3a6ODekE0pKo5CeUor3zQREfcbZK236upSC01nZ6cVXKFy8+NIS2/WsVdp8eepU3nK
DnEEucRR3MOWp7KHKrV/Xk2k6kMW6h9+9uxZ5nSEwgZAHNUuz3Jmen7b29ttV1RRcRR6zvPao0rE
Ud4XrqLiKJSntPLNawez1Nt79+7Z1hmNJZUNVndXKIyokExKbxZxFIo/b53KWnaII8gljiRS/G6y
SsSRwoo2+UYfKg2O1PghdanlSYeawP2w5+bmEEeAOFrhPM/MzJRd19DQkLkLJMtzntceVSKODh8+
bMcaOd68eVMTcRTKU1r5xpVPmo3N8htq3Kifnvn5+WV50TAIPw4NiciS3iziKBR/3jqVtewQR5BL
HGmAnxvorEOfNQOiiDjSvbdv3y6FdefOHVvRfTQQUbPN/AGJWdKhbriBgYHS4Mm2tjbEESCOViDP
esvXrCARHdSsrhF1bYjJycnUwbNZnvO89qgScRQdkK140n53zZ7S+BknTvxr086F8pRWvnHll2Zj
s9RbvaC62WF6yZRIjJbbiRMnzNevX20cSrs/IDstvWnlkDX+tDoVDT9P2SGOIJc4Ej09PVbN6w1E
44D8WQ55xJFw00x1aBbFu3fvys7rgVM8/htblnSIwcFBO/hQU2I1SwNxBIij2udZ3RYaF+Kmwztn
JLQ8R0dHh/1e1/gDeYvYm7z2qBJxJPTCJXuiFzbZlLRFBvVCp/PuGj+stHOhPKWVbxxpNjZLvX3+
/LkdEK64JC40oDlabioLlYvSK6HkD6pOS2+oHLLEn1anouHnLTvEEYadQgDgGSLPOZBTTuo+AkAc
YeQAeIYQRxsetUJrIK9bf0gtMqs9oBcQR4CRA+AZIs+rhmZKaf00ddFoheyrV69akQSAOMLIAQDP
EHYDAHGEkQMAniHyDIA4wsgBAM8QeQZAHPEDAQDPEHkGQBwBRg6AZ4g8AyCOACMHwDNEngEQR4CR
A+AZIs8AiCPAyAHwDJFnAMQRYOQAeIbIMwDiCDByADxD5BkAcQQYOQCeIfIMgDgCjBwAzxB5BkAc
AUYOgGeIPAMgjgBDB8CzQ94BNv6zw9OEoQPgmaEMAHhmEEfr50fj4ODIdgB2g4OjWnYDiwLA2zkA
ACCOABBHAACAOAJAHAEAAOIIAHEEAACIIwDEEQAAII4AEEcAAIA4AkAcAQAA4ggAcQQAAIgjAMQR
AAAgjgAQRwAAgDgCQBwBAADiCABxBAAAiCMAxBEAACCOABBHAACAOAJAHAEAAOIIAHEEAACIIwDE
EQAAII4AEEcAAIA4AkAcAQAA4ggAccRjAwCAOAIAxBEAAOIIABBHAACIIwBAHAEAII4AAHEEAACI
IwDEEQAAII4AEEcAAIA4AkAcAQAA4ggAcQQAAIgjAMQRAAAgjgAQRwAAgDgCQBwBAADiCABxBAAA
iCOANSOKogcAACCOABBHiCMAAMQRACwXSAAAgDgC4IFBHAEAII4AAHEEAIA4AgDEEQAA4ggAsgok
AABAHAEA4ggAAHEEEBIJHJvnAOo99R4QRwC0ngC/OWXAb04hII4AMBbAb0/egd8ecQSAkQDqAHkG
6gAgjgADAdQB8gzUAUAcAQYCqAPkGagDgDgCDARQB8gzUAcAcQQYCKAOkGegDgDiCDAQQB0gz0Ad
AMQRYCAyMzs7u6bCoQ6Q57Vax4F6jzgCqNBAfP/+3XR1dZnt27ebrVu3mo6ODvPt27eya8bGxsy+
ffvs+cOHD5uZmZnEeJ48eWJ+++0309zcnDtdaUZMcVeDaoWzHg084mg5S0tLpqGhIfWahw8fBsPJ
W++z1E3WpkIcAeIIVsnYXLlyxdy5c8f8+vXLHtevX7cCyfHq1SvT2tpq5ufn7fkHDx6YAwcOJMYj
B/H06dNC6UozYtUycOvVUCKOqp/nnz9/mjNnzqRe8+HDB3P8+PFg2eWt91nSijhCHAHiCFbJ2Oza
tcuKHt9h+G+wnZ2dZnBwMHMc0b2N4uJNEkRJaUzaM6m/v9/s3LnTtnp1d3eXvj979qyZnJwse6s/
efJkpr2X9P3Lly/Nnj17TEtLSzAu8ePHD3P+/Hmzbds209jYaKanp8vOS3DqPp2Xo/348WNqfPo9
Ll26ZHbs2GHq6upsy52fXtdKsWXLFnPo0CEzNTWFkyiQZ/0WEj9p17S3t5t///03KNyL1Hv/d08K
4/bt26a+vt7+1nECLK1eJtXlzVLfEUeII4CqGQgZPhkuhwxznrEQWd5+84qjuHN37941o6Oj1rBK
0Mmg3rx505779OmT7f7TOXWb7N+/37x9+zZTOej85cuX7b0KJxSX6O3ttV0vYnx8vKxl7datW2Z4
eLjUMqew5FjS4hsaGjI3btyw33358sUcPXq0LN2+k5yYmLD5w0nkz/OzZ89SrxkYGLC/XdZ6k7fe
R3/3uDBOnTpVEhf6zfXbZ3kGkuLYTPUdcYQ4Aqiagbh//741fr5hkkHSG6LeBOPGJK2GONLYDr/F
S/hGU0ZZRldGXV2HWctB5/033SxxyTlEzzsOHjxoBacvPnfv3p0an96o/Xtev35dlm6JV+eccBKV
5znuGnUnnzhxIle9yVvvo797XBhp14TqZdz9m6m+I44QRwBVMRBfv361XVJ6W/Tv04DthYWF0pug
utpWWxxJtEW7ItTsHjXyMszKV1EnlyUu/20+SjRN0euT4vNRufvXSazqs/LX19eHk6iyOFpcXLQO
+/PnzzUVR5WGEaqXRYXhRqnviCPEEUDFBkKC6Ny5c7ZZ20fjAPy3OhmutBlfKyWO4oxwFHVJ6C23
UnEUiivNWcSdC+U5dI/QuA11aWhMzLVr13ASVRRHFy5cMI8ePcoVzmqIo1C9LCqONkp9RxwhjgAq
MhASD2od0oy0KBrIHH2rU/daUSehOKohjjQwU61ZSWgGnsZNjIyM5O5WixKKS1PBk7oZdG+0m8EX
l3HxaXagf8/c3FxiurWsQlbjjzjKXmeTjlrU+6LiKFQvi4qjjVLfEUeII4DCBuLFixfm2LFjZV0I
Purr1+EGWGr2jAY7Z43HH0ypmUGnT58uJI4kyDRWwRlRDfx0gzh16LNmxggN9Dxy5EiZwdaMo7hw
spRTWlxCY7TU9C80Sy46QFVl5u6VaPPX1YmLT8slaDCwG6Da1tZWdp3C1wweER2ki5OojkDIe00l
9T6pjofEUaheFs3XRqnviCPEEUBhA7F3797gG7KMnQZF6g1QRt4JjSzxOGOmpnoZSRm5IuJIA6sV
v/8W2tPTY7v9XLrc7BcNGven8ut/nU8KJ0s5JcUlNCNOcSqfGpCqAaU+bmqzDs3ceffuXTA+LZ+g
8VKaTq1xXv516mJQPG56t3McOIm1I47y1PukOp6ldSmtXlaSr41Q3xFHiCMADARQB8gzUAf4vSkC
wEAAdYA8A3UAEEeAgQDqAHkG6gAgjgADAdQB8gzUAUAcAQYCqAPkGagDgDgCDARQB8gzUAcAcQQY
CKAOkGegDgDiCDAQQB2oRp7yrFwN1HtAHAFgIGBTiKOkRUxrlefZ2dkNW082Wt6wfYgjAAwE+Q6W
RdreYRvxqAVpmy+v97pai7xhAwBxBBgI8k1ZrGCeVqPlqBbhrpXfZ6PVE2wA4gggt4HQPkVuDyht
0Do1NVU6pw0wtTeSNsRsbGw009PTZeFpzyPtudbS0lL6vr+/3+6PpH2Vuru7l8WXdl5hjo6Omvr6
+tI+Sm7zziz3a+PKS5cu2T2h6urqzNjYGIZxk4ijvHnOUtfcHmGq/9p4VZvCxgmypPDzPh/RsOKu
XVxctPshan8zHz2ren7F+/fv7X5oSrfypWf38ePHmfK+Eq1u1HtAHMGaNxC+YdRO2/v37y+d0+7b
Dx8+tP+Pj4+X7b6t8C5fvmwFiduUUhtGyujqu58/f1pxos00HaHzClNG3Tmh6A7cofuHhoZKu4lr
d++jR49iGDe5k0gTL2l1TbvLDw8Pl3aXV93Ti0LWsizyfPhhpl3b1dVl0+ejui8xJZqamuxO9y7t
yodEWta803IEiCPY9E5CRtMJoCgSQzKuSeE54+pobm5edr0vtkLn48L00x26X2/oeoN2aLdwDCPi
KGv99a/VLvB+XdL/2jU+jzjK+3xkretv3761rUfuvP7u27dvWXw+aiHKmnfEESCOYNM7CbUW6ZyM
cV9f37JWpTzh6fpos7xvlEPn48L0v8sSvo+cBoYRcZT1e/87v17F1a8s4ijv85Gnrh87dsy2LAm1
EqklyEddemr57ezstEIvJH4QR4A4AhxjBBlSdZu1t7eba9euFRZHcQ4lz/kiDisk5jCMiKMidS1U
l4qIozz1P3StnleNJRIaa/Ts2bPSuXv37tlW35GREfu9uvUQR4A4AihoIGZmZsqua2hoSO1WiyIj
vbCwkBh+6HzIaIfub21tLesKmZubwzAijgrXtWi3mj/FvYg4ylP/Q9cKDajWWCN1qfloQoJ/7/z8
POIIEEcAeQyE3jA1Y01EB2aqWV7dbmJycnLZgOwoGiTqBkTr0GfN8sl6PmS0Q/ere2FgYKA0ILut
rQ3DiDgqJI5Ut27fvl2qa3fu3LEvCw7NBNO4HV9AhcLPU/9D1woN0NasTH9QtxNNbnaaXhAOHz6c
SxyF8ka9B8QRbHgnoS41jUlwU3qdUBKaLtzR0WG/1zUa4BwKr6enx7656i1b4yDcTJ0s50NGO0v4
g4ODduCspkBrxg+GEXFURBwJN5Vfh2aqvXv3rkyYqA4mLZhY5PnIW9e/fv1qz+lFwOf58+d28Lae
W73QaMJFHnEUyhv1HhBHgGME6gB5BuoAII4AAwHUAfIM1AFAHAEGAqgD5BmoA4A4AgwEUAfIM1AH
AHEEGAigDpBnoA4A4ggwEFQZ6gDiCKj3gDgCwEAA4gio94A4AsBAAHWAeg/UAcQRAAYCqAPkGagD
iCMADARQB8gzUAcAcQQYCKAOkGegDgDiCDAQQB0gz0AdAMQRYCCAOkCegToAiCPAQAB1gDwDdQAQ
R4CBAOoAeQbqACCOAAMB1AHyDNQBQBwBRgL47ck78NsD4ggwFsBvThkAvzkgjmBNGw2OzXMA9Z56
D4gjAOBNEgAAcQQAiCMAAMQRACCOAAAAcQSAOAIAAMQRAOIIAAAQRwCIIwAAQBwBII4AAABxBIA4
AgAAxBEA4ggAABBHAIgjAABAHAEgjgAAAHEEgDgCAADEEQDiCAAAEEcAiCMAAEAcASCOAAAAcQSA
OAIAAMQRAOIIAAAQRwCIIwAAQBwBII4AAABxBIA4AgAAxBEA4ggAABBHAIgjAABAHAEA4ggAAHEE
AIgjAADEEQAgjgAAEEcAgDgCAADEEQDiCAAAEEcAiCMAAEAcASCOAAAAcQSAOAIAAMQRAOIIAAAQ
RwCIIwAAQBwBrLAoih4AAIA4AkAcIY4AABBHALBcIAEAAOIIgAcGcQQAgDgCAMQRAADiCAAQRwAA
iCMAyCqQAAAAcQQAiCMAAMQRQEgkcGyeAwAAcQRA6wnwmwMA4ggAJwn89gCAOALAOQJ1AAAAcQQ4
RqAOAAAgjgDHCNQBAADEEeAYgToAAIA4AhwjUAcAABBHgGME6gAAAOIIcIy5mJ2dXVPh1DpM6kD1
88/B4qeAOALI7BiXlpZMQ0PDsu+/f/9uurq6zPbt283WrVtNR0eH+fbtW2I4T548Mb/99ptpbm7O
na5QGhV/NahWOGlhZjXOK2nEN7PDwFnymwPiCCCXofj586c5c+ZM7DVXrlwxd+7cMb9+/bLH9evX
rUBKQsLo6dOnhdIVMmbVMna1MJpFw0QckW/gtwfEEaxBI3H8+HHz4cOH2Gt27dplRZEvpJJaXuKa
tePCTBJEaWlMajLv7+83O3futC1b3d3dpe/Pnj1rJicnS5/VonXy5MlMTe/v3783p0+fNtu2bbNi
r7Gx0Tx+/LgsLS9fvjR79uwxLS0twXz/+PHDnD9/3oansKanpxPznJQflwelZ8uWLebQoUNmamoK
R0GegToAiCOohYF49uxZZiMiRy9RkDWeaomjuPN37941o6OjVrxJtI2NjZmbN2/ac58+fTKHDx+2
59RluH//fvP27dtM8TQ1NZkHDx6UWsuGh4fL8qz7L1++bM8pnlC+e3t7zcOHD+3/4+Pj5sCBA7HX
peVH+K1yExMTNk84CfIM1AFAHEENDUSWa+7fv2+d/VoQRxrX5LdqCV8wSGwMDQ1ZgaHuwUqMpVpr
/Ps/fvyYOd8SQ9F0xl0Xyo8EmhNZOAnyDNQBQBzBGhBHX79+td1VatVYC+JILSnRLi1fxDjBsXv3
bpv2PGWhbjOJwM7OTnPw4MFgOtPyrXRmyVMoP2ot0nfKU19fH06CPAN1ABBHsJriSILo3Llz5suX
L7nCKCKOksYFRcOKCqE4Tp06ZVtu8oije/fu2XtGRkZsl6O6zlZCHGXJj0Sbuuba29vNtWvXcBLk
GagDgDiC1RBHEhaazj8/P587jOhnhVGtliMNSl5YWEi8XrPsNIZHIidPt9qOHTvKwk1Lc5Z8a4mE
LN1qofz4zMzM5Db6iCPA9gHiCKAK4ujFixfm2LFj5vPnz4Xi8QcRa0acZoEVFUea7aWxPhoULm7d
umVu3LhRGjitz5p5J9Tac+TIkTLh8e+//8aGE6W+vr40O21ubs4O7A6lMxpmdEC2usSEZtAlDchO
y4/QfZqxJlSmaS1SOImNmef1sNgodQAQR7DhxdHevXtzrT4bPeecuLqM1IIi515UHGlgtZYR8JcS
6OnpsS09+k7Cy80e01pM/lR+/a/zSeH4PH/+3A6EVrolSDQIOpTOaJj+NZotp/QoPI1fev36dWJY
SfkR6lLT/SpLheWEEk4if54XFxft8goqZ41J07IJaYubrhVqsYCpI8sCrppBuW/fPpsOvTSoBRNx
BIgj4O0JqAMbIM8XL160gta10t2+fdsuhLqZf8PQAq6vXr0yra2ttptZZablLvxWUOo9II4AxwjU
gXWcZ7V8+OPA9L9a7NLC8Rf+dKQt2ql7NLhfLVM6r7Wx1IrooxXndU7dsupC9ZeIyLLYaN6FQZPi
y9IyrJmbg4OD1HtAHAGOEagDm0EcaaxYWpdV3MKfoUU73bILEiC6RkLKnxigMWVaYNS1Xik8dfWl
xZk2pi+0MGiW+NLQWLz1OOYJ24c4AsBAAHUgQ54lCtSV5lZQl2hJW0ohbuHP0KKdusffKkabOGsM
n0Pjx/xJAfpfrUxpcUbzk2dh0CzxpSEhJgGmLXDU8hTahJp6D4gjwEAAdWAd5VlOXQuayuFrooCc
fqjlKE4spC3aqc9R8eTPMIwTY/75LEtG5FkYtEh80bi1pIeWm3AtT+pqo94D4ghwjEAd2IB51pIN
dXV1ucIJLdqZJKji/o+7J4s4ElkXBi0Sn4/GZPktTxJItZw9R70HxBFgIIA6sIp5fvToUWorSFw4
oUU7dY8/1V2tVf6gb90f7ebyxUZWceQILQxaJD6fkydPln2WOFL3GvUeEEeAYwTqwAbIs6agSxCJ
9+/f21YXf/2pLOGEFu3UPfqsLXd0/s8//yxbLkDXu3FPOrSiu7r40uKMLjaaZ2HQIvH5aGyTDn/5
A611RL0HxBHgGIE6sAHyLCGk6fFuzFFoUHNSOGmLduoerbT++++/24HTV69eXTaA2U2t16FB4u/e
vUuNM7rYaN6FQfPGF0WCSHlx+XWrzlPvAXEEOMYNlPcsqwJTB8gz5U0dAMQRYCA2Td5DqwJTB8gz
5U0dAMQRbDIDofEWah7XWAYJBa1h4jZdFWkr8IZW501bPbhW4WosxKVLl2xXh2YfaWG+pLwnrQqc
Z9VinAR5TmI9zOSiDgDiCDAQMTQ1Ndk9ktwgS62gK8fvSFuBN+1caPXgWoU7NDRUGiSrgbBHjx7N
tVFukVWLcRLkGagDgDiCDW4g/PVb0lbgTTsXWj24VuGqNcefrqyBt3nEUZFVi3ES5BmoA4A4gg1m
INRN1Nvba9d5kTjwr01bgTftXGj14FqFG53KLCGVRxxVuoowToI8A3UAEEewzg2Edg3XWikjIyPm
2bNntqsoem3aCrxJ50KrB9cq3NAqwKFzla4ijJMgz0AdAMQRrHMDoYHL/iq/8/PzidemrcAbPRda
PbhW4ba2tpZ1i2lbiDziqNJVhHESK5+nPL8vYPsAcQQQNBD19fWl2WkSElrx1r82bQXetHOh1YNr
Fa4Glw8MDJQGZLe1teUekF3JKsI4idURR0kzD4vkeXZ2FoOBOALEEWxmA/H8+XM7oFkCRKJEA6H9
a9NW4A2tzpu2enCtwhWDg4N2ELWm+2u2Wd6WhUpXEV7rdSBJUGzUIy/VmIK/XrtiK03rat+POAJ+
bcBAwKavA7VoOapGOa3XskYcAeIIcIxAHdgg4ihvnpMWGo0TWXFh+N+FFh6N3l90cdQ4ksI6e/as
mZycLAv35MmT9n+No1OLqBY51aKv09PTsWmtNN+hvOZZsJV6D4gjwDECdaDGeU5baDR6T0gkhBYe
9f+vZHHUKGlhqatZ4wd1bmlpyYbz9u1be07Ldrh1xDQjVN3pRcRRKN/VXrCVeg+II8BAAHWghnlO
W2g0rzgKLTzq/1/J4qhRQmFJnEiASJBcuXKl9L3EUPS+IuIolO9qL9hKvQfEEWAggDpQwzynLTSa
VxyFFh6NXlt0cdQoobCcQNHkhK9fvyamt6g4CuW72gu2Uu8BcQQYCKAO1DjPSQuNViqO0kRGpYuj
+mQJ69SpU7alaCXEUd685l2wlXoPiCPAQAB1YIXyHF1oNCSOogulhhYercXiqFnC0hpdGvOj1e/9
bjWt21WkWy1vvqu9YCv1HhBHgIEA6kAN85y20KhmcWlzYee4/UHSHz58sGtr+eGGFh71/69kcdQo
aWFpQPaRI0fKhMq///5r/9eAbHXfCc1oSxqQXWm+q71gK/UeEEeAgYjAqsXUgWrmOW2hUQ1g1kKQ
bjFIJ1J0rVpddG003LSFR6PXFl0cNY6ksDo6Osqm8ut/nReavabzCl9xaSB0XForzXcor1nup94D
4gjWpGMsuqBenvuSrvX/r8aqxdQBxBFQ7wFxBFBVcbQScSddi4HDSZBnoA4A4ghWzECkrWIbWulX
Tea7du0yw8PDqS1AGsPhVuXVSr1JTflx/0enAzc1NS3LgxaZ27t3r1lcXOTHxkngGIE6gDgCKG4g
QqvYJgkX3aNpxm4wpQZ/pokczUz5/Pmzvf7Ro0fmwoULmcVR9H8N3Ixuq6D0XLx4kR8aJ4FjBOoA
4gigMgMRWsU2SaA4seNIWxVY//stRYpP8RYVR24NGB+ttvvmzRt+aJwEjhGoA4gjgMoMRGgV26wD
pNNWBY6L25+inFccifr6+tJeURJeEkeAkyDPQB1AHAFUbCBCq9imbYNQiTjyxVURcaT1Ubq6uuz/
Gsv0119/8SPjJMgzUAcQRwCVG4jQKrZJAkU7fmuskUNdWmnCxrXyCC2up8HTlYgjxa3B3era02By
rd0COAnyDNQBxBFAxQYitIpt1gHZuidN2Jw4ccLu76TrFV/eAdnRVYuFWoz++OMPc/nyZX5gnAR5
BuoAII6gegYibRXbUNeWWm3q6ursrLe0rjKd17W6RkJJQiePOIquWiymp6ftNayejZMgz0AdAMQR
rDkDoW4tv6tsJZCI08BswEmQZ6AOAOIIVt1AaD8kTal36yNdv37ddrOtFIpXLV59fX38uDgJ8gzU
AUAcweobiGfPntnp8+rm0grZV69etSJppdAYJHXPMRAbJ0GegToAiCPAQAB1gDwDdQAQR4CBAOoA
eQbqACCOAAMB1AHyDNQBQBwBBgKoA+Qb+O0BcQQYCaAOkHfgNwfEEWAogDqwsvnn2DwHII4AcIxA
HQAA7BxFADhGoA4AACCOAMcI1AEAAMQR4BiBOgAAgDgCHCNQBwAAEEeAYwTqAAAA4ghwjEAdAABA
HAHOEfjtAQAQR4CTBH5zAADEEaxFZ8nBSsEAAIgjAEQhhQAAgDgCAMQRAADiCAAQRwAAiCMAQBwB
ACCOAABxBAAAiCMAxBEAACCOABBHAACAOAJAHAEAAOIIAHEEAACIIwDEEQAAII4AEEcAAIA4AkAc
AQAA4ggAcQQAAIgjAMQRAAAgjgAQRwAAgDgCQBwBAADiCABxBAAAiCMAxBEAACCOABBHAACAOAJA
HAEAAOIIAHEEAACIIwDEEQAAII4AEEcAAIA4AkAcAQAA4ggAEEcAAIgjAEAcAQAgjgAAcQQAgDgC
AMQRAABg5QEQRwAAgDgCQBwBAADiCABxBAAAiCMAxBEAACCOAGokiqIHAAAgjgAQR4gjAADEEQAs
F0gAAIA4AuCBQRwBACCOAABxBACAOAIAxBEAAOIIALIKJAAAQBwBAOIIAABxBBASCRyb5wAAQBwB
0HoC/OYAgDgCwEkCvz0AII4AcI5AHQAAQBwBjhGoAwAAiCPAMQJ1AAAAcQQ4RqAOAAAgjgDHCNQB
AADEEeAYgToAAIA4AhxjYWZnZ/lREUcAAIgjqI1jvH79utmxY4fZtm2b6ejoMJ8/f17z+dm6dWvN
wn7y5In57bffTHNzc+z579+/m66uLrN9+3abDpXZt2/fEEcAAIgj2AjiaHBw0AwPD5tfv37ZY2Bg
wBw/fnxTO3oJo6dPnyaev3Llirlz506pzCQuJZAQRwAAiCPYAOJo//79tiUkKg7Swnn58qXZs2eP
aWlpKX3f399vdu7caVtTuru7l91z7949s3v3bnv+8uXLZmlpqewaCQydU+uVxNnHjx8T44zbO8y1
9mzZssUcOnTITE1NpZZHUnxZ9iXbtWuXFUWOnz9/1rQlC3EEAIA4glVyjAsLC1bkdHZ2poYjcSNx
8OnTJ/vd3bt3zejoqP1OQmFsbMzcvHmz7B51UUmA6BrFodYXx61bt8parxTe+fPnU+OM5sdv7ZmY
mLCiL4ks8eXhx48fVrghjgAAEEewgcTR2bNnbUuKjjdv3qSG47fqCAkfvyVF+OJE90xPT5c+q6Vq
7969pc8HDx60AsMXG2plSoszmh+Jk4cPH2Yqiyzx5eH+/fumt7cXcQQAgDiCjSSOHOpuUrdUnnDU
ahPtjlL3ln9PVDz5XXf+tXHn4+KMfqfWItdC1dfXl5rHIvEl8fXrVyss1WKGOAIAQBzBBhRHcvKh
MUdZxEYWQRX3f9w9WcSR0Lik8fFx097ebq5du5aYniLxJZXVuXPnzJcvXzZUHQAAQBzBphZH6o7y
nXu0iylLOGpp0niltHtmZmZKnzXtXUsH+PdHu7n8Ac5ZxZFDcaWdLxJfFLUYaTr//Pz8hhPIAACI
I9jU4kjdaOqGcoOT//zzT3vkCUcDnG/cuFEKQ5/95QB0jz5LhLk4zpw5U3b/7du3S/drmnxDQ0Nq
nJplpnFITuQcOHDAzlgTGpid1vpVJD6fFy9emGPHjq2L9aAQRwCAOALI6RjVNaSZYGo50WBsiaUi
4fT09NjWIIVz+vTp0qwyd8/jx4/N77//bluqrl69umzRRDe1Xodmjr179y41Ts2GU1yuxUddahpo
rS4+CSMnlJLIG5+PBpNHx1itB+GBOAIAxBHAGnGMOGXqAAAA4ghwjDhl6gAAAOIIcIzxrIfVo6kD
AACII8AxAnUAAABxBDhGoA4AACCOAHCMQB0AAMQRAI4RqAMAgDgCwDECdQAAEEcAtXKMs7OzFBzi
CAAAcQQ4Rkc1puAX2dB1tZx+peGs9v2IIwBAHAHU2DFWw5muJ4eMOAIAQBwB4sjuQaa9yLQnmXar
n5qaKl0f3TcsLgz/O23ieunSJbvHWl1dnRkbG0ttOerv7zc7d+60+5t1d3dnSlcob/p/dHTU1NfX
l/ZZ00a0Dm1Uq73UtHFtY2OjmZ6eTgynkryG8pflfsQRAADiCFbBMfriYWJiwuzfvz/xnpBgGBoa
Mjdu3LCO/8uXL+bo0aOJguPu3btWxOhabX4rcaDNZLOkKySOtPHtx48f7WeFobAcvb295uHDh/b/
8fFxc+DAgULiKJTXUP5C9yOOAAAQR7BK4mjPnj0lsRC6JyQYWlpabMuM4/Xr14mCo7m52QoDH18A
paUrJI6cMIo7LzEUjbeIOArlNZS/0P2IIwAAxBGskjhSq4zOyZn39fVVJI78FhohcZAkOHRttOtO
3WBZ0lWJqImmsVrhRPMayl/ofsQRAADiCFZJHImXL1/aLqb29nZz7dq1qomjNMHhC4W86VqL4ihv
/kL3I44AABBHsIriyDEzM5MqEKKf5+fny75rbW0t6yqam5tLDE+DrBcWFjKlPZquSkRNQ0NDoW61
vHkN5S90P+IIAABxBKskjjQGRzPDRHTwsmZ0afyOc+L+IOkPHz7Ygc9+uA8ePDADAwOlQcZtbW2J
guPWrVulAck69Pn48eOZ0lWJONKAbHXZicnJycQB2ZXmNZS/0P2IIwAAxBGskjhS19XBgwdL096d
IBGaXaWFIN1ikE6k6Fq1wOjaaLiDg4Nm9+7ddgq7ZmylCZeenh47lV3hS3x8+vQpU7oqEUdLS0um
o6PDhqnwNRA67rpK8xrKX5b7EUcAAIgjwDECdQAAAHEEOEagDgAAII4AxwjUAQAAxBHgGIE6AACA
OAIcI1AHAAAQR4BjBOoAAADiCHCMQB0AAEAcAY4RqAMAAIgjwDGuKrOzszW9njoAAIA4gk3sGNey
w0xa+dqt2J2V6PWbVSQgjgAAcQSwzh1jtQQdooByAADEEUAhoaH/R0dHTX19fWlPM7f5ahLXr1+3
+4ft2bPH3Lt3L9c+Z+/fv7d7jmmDW8XV2NhoHj9+nJg299c/QuHEXa+/i4uLZu/evXavNR9tsnvo
0KHS5/7+frv32fbt2013dzfiCAAAcQSbTRxJZHz8+NF+dpuvJjE0NFTaWV6bqra0tOQSR01NTXZ3
erdz/fDwsBVZaeIoLtw84fifu7q6zK1bt5blSYJIaDNYiUWF+fPnTzM2NmY340UcAQAgjmATiSMn
jLI41Obm5rKWl+np6VziKA61WOUVR3nC8T+/ffvWth5J/Aj93bdvX6kMlD93zrF//37EEQAA4gg2
kzjK41CjrUoSEnnDe/nypent7TWdnZ3m4MGDmQRRXLhZw4l+PnbsmG0dEmp9UsuZn79ot5wvuhBH
AACII0AcpYqjvOFpjNKBAwfMyMiIefbsme2aKyKO8oQT/Tw+Pm7HKAmNNdL9jvUshBBHAIA4AlgF
cXTkyBHz7du30ue5ubnU8Obn58u+00DuhYWFxPNZxVGecOI+awC6xhqpS81HYskPF3EEAIA4AsRR
qkN99OiRna2m7rQvX76Ytra2suv92W4fPnywXVb+eYkSN6tMwurw4cOZBJFmpWlckGaWZQknen00
TxpkXVdXt2ywtQZr37hxozTQW5+PHz+OOAIAQBwB4igZzejSzLDff//dChT/ejfbTd1TDQ0N5smT
J2Xnnz9/bgc46xp1iz18+DCTOJKI0cKObnHHUDjR66N5+vr1qz0ngRelp6fHtkzpvMSduuwQRwAA
iCPYwOIIB0wdAABAHAGOEQdMHQAAQBwBjnFlqkzefc8AcQQAgDgCHCNQBwAAEEeAYwTqAAAA4ghw
jEAdAABAHAGOEagDAACII8AxAnUAAABxBDjGZGZnZyl0xBEAAOIIcIyO6JT+WsaP06ecAAAQR7Dm
HWNos1dAHAEAII5gTTpG7Xfm9j/TLvRTU1Pm3bt3pqmpadm1P3/+NHv37jWLi4s2vNHRUbvpq+71
N5nVOf9w392+fTv2ekd/f7/ZuXOn2b59u+nu7g6mMy5vaddRBzAbAIA4Agg6Rl+kTExM2A1cRVtb
2zJhITF08eLFUnjaiFW73Qu3yWxSfPp86tSpxOu1ga3C//XrlxVhY2NjdsPYUDqjcaVdRx3AbAAA
4ggg6Bj37Nljd7GPMj4+btrb28u+a2lpMW/evCmF54ROXBxx4ijt+ubmZiuMfHxhk5TOaDhp11EH
MBsAgDgCCDpGta7onMRJX19f2Tl1gb19+9b+//r1ayuO0sILiaO069XiE+2OU9dYlnT64aRdRx3A
bAAA4gggk2N8+fJlqaXo2rVrpe8HBgZMV1eX/f/8+fPmr7/+qpk48oVQ3nRGw066jjqA2QAAxBFA
Lsc4MzNTdt2XL1/Mtm3bzOfPn+1A6aWlpZqJIw2eXlhYyJSXaDqT8ha9jjpAWQAA4ggg6BgPHDhg
Z3iJ6CBpoRajP/74w1y+fDmX2JGo0hijHz9+ZLr+1q1b5saNG3bckQ59Pn78eKZ0+uGE8kMdAABA
HAGkOkZ1QR08eLA0vd4JC8f09LS9N7ridUjsaKaZFoJ0i0GGrhc9PT1mx44d9h7NhPv06VOmdPrh
hPJDHQAAQBwBVOQYJVA0MBsQRwAAiCPY9I5R3VtqzWHWF+IIAABxBDhG83/jhk6cOFE2EBsQRwAA
iCPAMQJ1AAAAcQQ4RqAOAAAgjgDHCNQBAADEEeAYgToAAIA4AhwjUAcAABBHgGME6gAAAOIIAMcI
1AEAQBwB4BiBOgAAiCMAHCNQBwAAcQSAYwTqAAAA4ghwjEAdAABAHAGOEagDAACII8AxAnUAAABx
BDhH4LcHAEAcAU4S+M0BABBHsFrOkmPzHAAAiCMAoAUFAABxBACIIwAAxBEAII4AAABxBIA4AgAA
xBEA4ggAABBHAIgjAABAHAEgjgAAAHEEgDgCAADEEQDiCAAAEEcAiCMAAEAcASCOAAAAcQSAOAIA
AMQRAOIIAAAQRwCIIwAAQBwBII4AAABxBIA4AgAAxBEA4ggAABBHAIgjAABAHAEgjgAAAHEEgDgC
AADEEQDiCAAAEEcAiCMAAEAcAQDiCAAAcQQAiCMAAMQRACCOAAAQRwCAOAIAAMQRAOIIAAAQRwCI
IwAAQBwBII4AAABxBIA4AgAAxBEA4ggAABBHAIgjAABAHAGssCiKHgAAgDgCQBwhjgAAEEcAsFwg
AQAA4giABwZxBACAOAIAxBEAAOIIABBHAACIIwDIKpAAAABxBACIIwAAxBFASCRwbJ4DAABxBEDr
CfCbAwDiCAAnCfz2AIA4AsA5AnUAAABxBDhGoA4AACCOAMcI1AEAAMQR4BiBOgAAgDgCHCNQBwAA
EEeAYwTqAAAA4gg2mGOcnZ2loBFHAACII1jfjvHbt2/m9OnTZtu2bWb79u3m7Nmz5suXL4Xi2Lp1
a1XTWStnXq1wKw1npe9HHAEA4gggg2Ps7+83fX195tevX/a4f/++6enpWTXRsZ4cOOIIAABxBBtQ
HJ04ccLMzc2VPv/8+dOcPHkyMZwnT56Y3377zWzZssUcOnTITE1NlcKP7ucVF6f/ncTYpUuXzI4d
O0xdXZ0ZGxtLbTmSkNu5c6dt4eru7s6UrlBZ6P/R0VFTX19v71UYT58+LZ3/8eOHOX/+vG1Za2xs
NNPT04nhVJLXUP6y3I84AgDEEUAVHKOcrRxv9LskfPEwMTFh9u/fnxhHSDAMDQ2ZGzdu2PjVlXf0
6NFEwXH37l0rYnStBJzEwc2bNzOlKySO1K348eNH+1lhKCxHb2+vefjwof1/fHzcHDhwoJA4CuU1
lL/Q/YgjAADEEVRJHPlCIO07x549e0piIRRHSDC0tLTYlhnH69evEwVHc3PzMhHnC6C0dIXEkRNG
ceclhqLxFhFHobyG8he6H3EEAIA4giqJI3Ul5RFHapVRWHLmGqtUiTiKxiNxkCQ4dG20685Pe1q6
KhE1aWVRSTjRvIbyF7ofcQQAgDiCKomjuC60tG418fLlS9vF1N7ebq5du1Y1cZQmOOJEXNZ0rUVx
lDd/ofsRRwAAiCOokjiSkPj+/Xvp89LSkjl+/HimMGdmZlIFQvTz/Px82Xetra1lXUUaGJ4UngZZ
LywsFEpXJaKmoaGhULda3ryG8he6H3EEAIA4giqJI82QcgN9dYyMjKR2S2kMjmaGiejgZc3o0vgd
58T9QdIfPnywA5/9dDx48MAMDAyUBhm3tbUlCo5bt26VpVOffRGXlq5KxJEGZKvLTkxOTiYOyK40
r6H8he5HHAEAII6gSuLo06dP1tFqAUcdp06dsgtDJqGuq4MHD5amvTtBIjS7yoXjixRdqxYYXRtN
x+DgoNm9e7edwq4ZW2nCResvqctP4Ut8KO1Z0lWJOFJLWkdHhw1T4WsgdNx1leY1lL8s9yOOAABx
BIBjBOoAAADiCHCMQB0AAEAcAY4RqAMAAIgjwDECdQAAAHEEOEagDgAAII4AxwjUAQAAxBHgGIE6
AACAOAIcI1AHAAAQR4BjrAmzs7OFzlXjeuoAAADiCDaoY1zPDtOtxB2Xl+i5SsJCHAEAII5gE4mj
jZonttZAHAEA4gigkGOM7jM2Ojpq6uvrS3uUuc1Uk7h+/brdD2zPnj3m3r17ufYte//+vd1DTBvW
Kq7Gxkbz+PHjTOnROf/ww447lxZXUliLi4tm7969dn81H22se+jQodJnbd6r/c62b99uuru7EUcA
AIgj2EjiSALi48eP9nNod/uhoaHSTvHaJLWlpSWXOGpqarK7zbud6IeHh63IypqeaPhpcWeJKy6s
rq4uc+vWrWX5liAS2gBWAk5h/vz504yNjdkNeBFHAACII9gg4sgJkSwOtbm5uaxVZXp6Opc4ikMt
RFnTk0ccZYkrLqy3b9/a1iOJH6G/+/btK6VLZeDOOfbv3484AgBAHMFGEUd5HGq0VUkiIW94L1++
NL29vaazs9McPHgw1/15xVGeuPzPx44ds61DQq1Pas3yyyDaLeeLLsQRAADiCDaxOMobnsYoHThw
wIyMjJhnz57ZrrlaiaO8cfmfx8fH7RglobFGut+xVoUQ4ggAEEcAqyCOjhw5Yr59+1b6PDc3lxre
/Px82XcayL2wsJB4vpriKG9c0c8aFK6xRupS85FY8sNFHAEAII5gE4ujR48e2dlq6k778uWLaWtr
K7ven1324cMH2x3ln5fgcDPGJKwOHz6cKz2aeaaxP5o9FjoXiistLKFB1nV1dcsGW2uw9o0bN0oD
vfX5+PHjiCMAAMQRbEZxJDRb6/+1d/8gVb1/HMDnkJAgpMEpiBAJEaGpQSRwcHD/DtIkOEg4uEmE
iFtDNIQQ0hASLhHSEEGIhDgIIhEOEjSEiLSIg4jD8+Nz4sjxeD3n3m+/4v5+vV4geO99zp97fPDz
5pznnCfu+rpx40YWPort87vL4tLTrVu30rt37859vra2lg1ejjZxyWt5ebml/YmgEg9vzB/gWPVZ
3baq1hV+/PiRfRYhsGxmZiY7MxWfRwCMS3bCEYBwxP9oOFKA9QEA4QiFUQHWBwCEIxTGP9NlWp3T
DOEIQDhCYUQfABCOUBjRBwCEIxRG9AEA4QiFEX0AQDhCYUQfABCOUBgv9/nzZwddOAIQjlAYc+Vb
+n/n9hV9xwlAOKLtC2PdRK4IRwDCEW1ZGGO+s3z+s5hhfnV1Ne3u7qa+vr4LbU9PT1N3d3c6OjrK
1re4uJhN6BrLFieZjc+KP/l7T58+bdg+Nzs7mzo7O1NHR0eampqq3c9G362qnT7g3wYgHEFtYSyG
lPfv32eTs4ahoaELwSLC0Pj4+Nn6YpLVmMk+5JPMXra9eD0yMnJp+5jANtYfM9tHCFtaWsomg63b
z/K2qtrpA/5tAMIR1BbGrq6ubIb6spWVlTQ8PHzuvYGBgbS1tXW2vjzoNNpGo3BU1b6/vz8LRkXF
YHPZfpbXU9VOH/BvAxCOoLYwxtmV+CzCyePHj899FpfAdnZ2st83NzezcFS1vrpwVNU+zviUL8fF
pbFm9rO4nqp2+oB/G4BwBE0Vxo2NjbMzRdPT02fvz83NpYmJiez3sbGxtLCw8NvCUTEItbqf5XVf
1k4f8G8DEI6gpcK4vb19rt3BwUG6cuVK2t/fzwZKHx8f/7ZwFIOnDw8Pm/ou5f287LuV2+kDjgUg
HEFtYezp6cnu8ArlQdIhzhiNjo6mycnJlsJOhKoYY3RyctJU+ydPnqT5+fls3FH8xOvBwcGm9rO4
nrrvow8ACEdQWRjjElRvb+/Z7fV5sMitr69ny5afeF0XduJOs3gQZP4wyLr2YWZmJl29ejVbJu6E
29vba2o/i+up+z76AIBwBL9UGCOgxMBshCMA4Yi/vjDG5a04m+OuL+EIQDhCYUw/xw3dv3//3EBs
hCMA4QiFEX0AQDhCYUQfABCOUBjRBwCEIxRG9AEA4QiFEX0AQDhCYfzzyg+PRDgCEI5o+8IYM9mP
jIz8lu3mT8j+fw8Nza4jnvz98eNH4QhAOKKdA0B/f3/a2dn5awvyn9zHOM4DAwPCEYBwRLsGgE+f
PmUPeiy3ffHiRbp+/Xq6du1aev36dTYRbMx7FvOVxYSuRbOzs6mzszN1dHSkqampc+sp/oSvX79m
Z0/iAZOxrtu3b6c3b95U7nvdMrHuxcXFbJqTfE614j42s/zu7m7q6+u7sO3T09PU3d2djo6Osnna
YvnYxp07d9Lq6mrD41vVLsTxjuMuHAEIR7RhOHr48GF6+fLlhbYPHjzIgsHbt2+zUDQ+Pp69Ls90
//z58yyYxFQj8fnS0lI26exl240A8urVq6x9/Dx79ix1dXVV7nvdMrGNCD/fv3/PXpf3sZnlw9DQ
0IUgE98tvnsohq64FHnz5s2G37OqXYjgGcddOAIQjmjDcHT37t305cuXC23zoJG/Pjw8bLiuuCQX
gaPostBwmTjD0qriMuX9bWa75eXDyspKGh4ePtcuLoFtbW1lv0egWl5erj2+Ve1CHO847sIRgHBE
G4ajuNRUDjfltlWv4yxJ+fJZo+BRtLGxkR49epT++eef1Nvb21TRrlqm0fLl95pdPi7N5eOvNjc3
z40PirNA0TYCYXky3uI6qtqFON5xCVI4AhCOaMNw1OisTSvhqO6sT3nZuITX09OTXVr68OFD2tvb
O2vTaIxS3TLNhKNWlp+bm0sTExPZ72NjY2lhYeFCyMrPME1PT1eGsUbtiqFSOAIQjmjDcPSrZ45i
wHHxklvddmP8UrH9t2/faot23TJ14aiV5Q8ODrJjsr+/nw0yPz4+brhP29vbtfvQqF2IsVnOHAEI
R7RpOIqxL3H56N+Go7iLbX5+/mywc7weHBw8F75iPNDJyUn2Oi5b5XeK5WNv6op23TJ14ajV5eOM
0ejoaJqcnDz3fpx9ijvRQnnQd3EdVe1CjGEy5ghAOKJNw1HcNRV3nP3bcBRmZmayszPxwMe4aywu
W+XizrV4P38Y5NraWjZgOwJDhIgYuFxXtOuWqQtHrS6/vr6evVd+undcKovxSvnjAvIAVF5HVbsQ
l+rcrQYgHNGm4SiCQPFMDykLd3G26Xe5d+9eFqCEIwDhiDYMRyHuqjIH2k9xaTDOhDW6y+y/IS7r
xfFutz4AIBwhHBXEuJgYY8PPMVLxBOvLBmL/qjjO5lYDEI5o83CEPgAgHKEwog8ACEcojOgDAMIR
KIzoA4BwBAoj+gAgHIHCiD4ACEegMKIPAAhHKIzoAwDCEQoj+gCAcITCiD4AIByhMKIPAAhHKIzo
AwDCEQoj+gCAcITiiL89gHCEIom/OYBwRNsWSz9/zw/A3+I/38t7B7PojZEAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-07-14 06:38:59 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-14 06:38:59 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVUAAAGRCAIAAABaF7fbAAARcUlEQVR42u3dv45cVRLH8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-05-02 09:33:58 +0100" MODIFIED_BY="Karen Welch">
<APPENDIX ID="APP-01" MODIFIED="2013-05-02 09:33:58 +0100" MODIFIED_BY="Karen Welch" NO="1">
<TITLE MODIFIED="2012-05-30 12:00:27 +0100" MODIFIED_BY="Karen Welch">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-02 09:33:58 +0100" MODIFIED_BY="Karen Welch">
<TABLE COLS="3" ROWS="66">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>890</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>382</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>753</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>710</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>751</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2146</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>379</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD) </P>
</TD>
<TD ALIGN="RIGHT">
<P>16775</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>4842</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1368</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>706</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>974</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1352</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>peripheral near/3 dis* </P>
</TD>
<TD ALIGN="RIGHT">
<P>3203</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>arteriopathic </P>
</TD>
<TD ALIGN="RIGHT">
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(claudic* or hinken* or IC) </P>
</TD>
<TD ALIGN="RIGHT">
<P>3350</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(isch* or CLI) </P>
</TD>
<TD ALIGN="RIGHT">
<P>16663</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>dysvascular* </P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>176</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>227</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>136</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(aort* or *iliac or *femoral or popliteal or femoropop* or fempop* or crural) near/3 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1044</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>719</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>250</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>151</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Vein] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>38</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Vein] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>60</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Vein] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>197</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>Fontaine </P>
</TD>
<TD ALIGN="RIGHT">
<P>421</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 </P>
</TD>
<TD ALIGN="RIGHT">
<P>41344</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>432</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis Implantation] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>456</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>bypass or surgery or construct* or reconstruct* or re-construct* or re-vasculari* or revasculari* or graft* </P>
</TD>
<TD ALIGN="RIGHT">
<P>110186</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Surgical Procedures] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>11042</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>#33 or #34 or #35 or #36 </P>
</TD>
<TD ALIGN="RIGHT">
<P>113165</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>MeSH descriptor: [Homocysteine] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>803</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>MeSH descriptor: [Hyperhomocysteinemia] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>185</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>hyperhomocyst* or hyper-homocyst* or homocyst* </P>
</TD>
<TD ALIGN="RIGHT">
<P>1453</P>
</TD>
</TR>
<TR>
<TD>
<P>#41</P>
</TD>
<TD>
<P>#38 or #39 or #40 </P>
</TD>
<TD ALIGN="RIGHT">
<P>1453</P>
</TD>
</TR>
<TR>
<TD>
<P>#42</P>
</TD>
<TD>
<P>MeSH descriptor: [Folic Acid] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>1999</P>
</TD>
</TR>
<TR>
<TD>
<P>#43</P>
</TD>
<TD>
<P>MeSH descriptor: [Vitamin B 12] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>530</P>
</TD>
</TR>
<TR>
<TD>
<P>#44</P>
</TD>
<TD>
<P>MeSH descriptor: [Vitamin B 6] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>497</P>
</TD>
</TR>
<TR>
<TD>
<P>#45</P>
</TD>
<TD>
<P>MeSH descriptor: [Betaine] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>62</P>
</TD>
</TR>
<TR>
<TD>
<P>#46</P>
</TD>
<TD>
<P>(folic or folinic) near/3 acid </P>
</TD>
<TD ALIGN="RIGHT">
<P>2656</P>
</TD>
</TR>
<TR>
<TD>
<P>#47</P>
</TD>
<TD>
<P>betain* </P>
</TD>
<TD ALIGN="RIGHT">
<P>113</P>
</TD>
</TR>
<TR>
<TD>
<P>#48</P>
</TD>
<TD>
<P>vitamin near/3 6 </P>
</TD>
<TD ALIGN="RIGHT">
<P>582</P>
</TD>
</TR>
<TR>
<TD>
<P>#49</P>
</TD>
<TD>
<P>vitamin near/3 12 </P>
</TD>
<TD ALIGN="RIGHT">
<P>846</P>
</TD>
</TR>
<TR>
<TD>
<P>#50</P>
</TD>
<TD>
<P>MeSH descriptor: [Niacin] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>267</P>
</TD>
</TR>
<TR>
<TD>
<P>#51</P>
</TD>
<TD>
<P>niacin* </P>
</TD>
<TD ALIGN="RIGHT">
<P>741</P>
</TD>
</TR>
<TR>
<TD>
<P>#52</P>
</TD>
<TD>
<P>MeSH descriptor: [Creatine] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>591</P>
</TD>
</TR>
<TR>
<TD>
<P>#53</P>
</TD>
<TD>
<P>creatine </P>
</TD>
<TD ALIGN="RIGHT">
<P>2945</P>
</TD>
</TR>
<TR>
<TD>
<P>#54</P>
</TD>
<TD>
<P>MeSH descriptor: [Phosphatidylcholines] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>271</P>
</TD>
</TR>
<TR>
<TD>
<P>#55</P>
</TD>
<TD>
<P>phosphatidylcholine </P>
</TD>
<TD ALIGN="RIGHT">
<P>287</P>
</TD>
</TR>
<TR>
<TD>
<P>#56</P>
</TD>
<TD>
<P>MeSH descriptor: [Pyridoxine] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>301</P>
</TD>
</TR>
<TR>
<TD>
<P>#57</P>
</TD>
<TD>
<P>pyridox* </P>
</TD>
<TD ALIGN="RIGHT">
<P>700</P>
</TD>
</TR>
<TR>
<TD>
<P>#58</P>
</TD>
<TD>
<P>*cobalamin </P>
</TD>
<TD ALIGN="RIGHT">
<P>460</P>
</TD>
</TR>
<TR>
<TD>
<P>#59</P>
</TD>
<TD>
<P>MeSH descriptor: [Acetylcysteine] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>513</P>
</TD>
</TR>
<TR>
<TD>
<P>#60</P>
</TD>
<TD>
<P>*acetylcysteine </P>
</TD>
<TD ALIGN="RIGHT">
<P>877</P>
</TD>
</TR>
<TR>
<TD>
<P>#61</P>
</TD>
<TD>
<P>MeSH descriptor: [Tamoxifen] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>1748</P>
</TD>
</TR>
<TR>
<TD>
<P>#62</P>
</TD>
<TD>
<P>tamoxifen </P>
</TD>
<TD ALIGN="RIGHT">
<P>3115</P>
</TD>
</TR>
<TR>
<TD>
<P>#63</P>
</TD>
<TD>
<P>aminothiol* </P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>#64</P>
</TD>
<TD>
<P>#42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 </P>
</TD>
<TD ALIGN="RIGHT">
<P>13071</P>
</TD>
</TR>
<TR>
<TD>
<P>#65</P>
</TD>
<TD>
<P>#32 or #37 </P>
</TD>
<TD ALIGN="RIGHT">
<P>140868</P>
</TD>
</TR>
<TR>
<TD>
<P>#66</P>
</TD>
<TD>
<P>#41 and #64 and #65 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>220</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 reports of 2 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;26 full text records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;402 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified from:&lt;/p&gt;&lt;p&gt;CENTRAL 220&lt;/p&gt;&lt;p&gt;World Health Organization Clinical Trials Registry 77 records for 73 trials&lt;/p&gt;&lt;p&gt;ClinicalTrials.gov 177 studies&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="201"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;26 records identified from the Specialised Register&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;376 not relevant from TSC screening titles or abstracts&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;14 further records not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 reports of 6 studies excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>